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resumo 
 
 
A detecção de recidivas antes da manifestação dos primeiros sintomas é 
essencial para atingir bons resultados na gestão de doenças neoplásicas. O 
antigénio carcinoembrionário é o marcador tumoral bioquímico para cancro 
colorectal mais usado desde há já muitos anos mas a sua variabilidade na 
detecção de recidivas é elevada. Este trabalho propôs-se a identificar 
parâmetros que, associados a antigénio carcinoembrionário, melhorem a 
detecção de recidivas de cancro colorectal entre dados bioquímicos, clínicos e 
clinico-patológicos de pacientes submetidos a cirurgias de intenção curativa 
para essa mesma patologia, utilizando registos retrospectivos clínicos diários 
dos serviços de Cirurgia Geral e Oncologia do Hospital Infante D. Pedro E.P.E 
em Aveiro. 
 
Recorrendo a análise estatística descritiva tradicional e multivariada, a glucose 
sérica e o antigénio carcinoembrionário sérico foram identificados como 
factores de prognóstico de recidivas colorectais. A desidrogenase láctica 
contribui para o diagnóstico de recidivas quando o antigénio 
carcinoembrionário não é considerado na análise. Outros dois parâmetros, o 
antigénio carbohidrato 19-9 e os leucócitos totais foram também relacionados 
com a ocorrência de recidivas em análise univariada mas perdem valor quando 
incluídos no modelo multivariado perante a presença do antigénio 
carcinoembrionário. 
  
Os resultados são apenas indicativos devido à reduzida dimensão da amostra 
utilizada mas abrem caminho a estudos subsequentes que avaliem estes e 
outros parâmetros. 
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abstract 
 
The accurate detection of recurrences, prior to the onset of the first clinical 
symptoms, is essential for achieving favorable results in the management of 
neoplastic diseases. Carcinoembryonic antigen has been a long-standing 
biochemical tumor marker for colorectal cancer and is the most widely used in 
this disease. However, it presents great variability in the detection of 
recurrences. Henceforth, the identification of additional parameters is of great 
importance. This work proposed to retrospectively analyze clinical, 
clinicopathological and biochemical data of patients that had undergone 
surgical resection of primary colorectal cancer, collected during the daily 
practice of the Surgery and Oncology Services of the Infante D. Pedro E.P.E 
Hospital in Aveiro, to identify parameters that, associated with 
carcinoembryonic antigen, improve the detection of colorectal cancer 
recurrences  
 
By means of traditional descriptive and multivariant statistical analysis, serum 
glucose and carcinoembryonic antigen were identified as prognostic factors for 
colorectal recurrences. Lactate dehydrogenase contributes to the diagnosis of 
recurrences when carcinoembryonic antigen is no considered in the analysis. 
Other two parameters, carbohydrate antigen 19-9 and total white blood cell 
count were also found related with recurrence in univariant analysis but lost 
significance when compared with carcinoembryonic antigen in the multivariant 
analysis. 
 
The results are merely indicative due to the reduced size of the patient sample 
but lay ground for subsequent, more powerful studies. 
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CHAPTER 1: INTRODUCTION 
 
The scope of this dissertation was to establish the relationship between some biological parameters 
and the prediction of recurrence of colorectal cancer. 
 
In this chapter, we discuss the three concepts involved: anatomy and histology of the digestive 
tract, colorectal cancer and tumor markers. 
 
1.1. OVERVIEW OF THE DIGESTIVE SYSTEM 
 
1.1.1. Anatomy 
 
The digestive system is constituted by the gastrointestinal tract, a hollow tube that extends from the 
mouth to the anus, and its accessory organs, primary glands that secrete fluids into the tract (Graaff, 
2001). 
 
The GI tract can be divided in several regions, each with its associated accessory organs (Table 1.1 
and Figure 1.1). 
 
Most of the digestive viscera are located within the abdominal cavity. Some of these viscera are 
covered by a serous membrane, composed of simple squamous epithelium and connective tissue, 
continuously secreting a serous fluid to lubricate the associated organs, providing protection, 
support and structural passage for vessels and nerves.  This membrane is called Peritoneum 
(Graaff, 2001). 
 
The peritoneum has a portion that lines the abdominal cavity’s wall, the parietal peritoneum, and 
another that covers the internal organs, the visceral peritoneum. Two layers of parietal peritoneum 
come together in the posterior abdominal cavity to form a fold, the mesentery, supporting the GI 
tract and allowing passage of the nerves and vessels. The kidneys, the adrenal glands, the 
abdominal aorta, the urinary bladder, most of the pancreas, the duodenum, the ascending and 
descending colon, as well as the rectum, are located behind the parietal peritoneum, lying against 
the abdominal wall, being designated as retroperitoneal (Graaff, 2001). 
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Table 1.1 - Digestive system: GI tract and associated organs. Adapted from Graaff, 2001; Seeley et al., 2004; 
Standring, 2011 
GI tract regions Functions Accessory organs 
Oral cavity Ingestion; mastication; digestion; deglutition. Salivary glands 
Pharynx  Deglutition.  
Esophagus Propulsion.  
Stomach 
Storage; digestion; absorption; mixing and 
propulsion. 
 
Small 
Intestine 
Duodenum 
Neutralization; digestion; absorption; mixing 
and propulsion; excretion. 
Liver 
Gallbladder 
Pancreas 
Jejunum 
Ileum 
Large 
Intestine 
Cecum 
Absorption (water and electrolytes); 
formation, storage and expulsion of feces. 
 
Colon  
Rectum  
Anus  
 
 
 
Figure 1.1 - Organs of the digestive system (Guyton, 2005). 
 
1.1.1.1. Large Intestine 
 
The large intestine can be subdivided in several regions: cecum, colon, rectum and anal canal 
(Figure 1.2). Being about 1.5 meters long, it comprehends about one fifth of the whole intestinal 
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length and extends from the end of the small intestine, the ileum, to the anus.  Its aspect differs 
markedly from the small intestine, with a larger diameter, a sacculated shape forming the haustra, 
and the appendices epiploicae. The organization of the muscle fibers is also different, forming three 
longitudinal bands, the taeniae coli, that converge on the basis of the vermiform appendix and run 
along the entire length of the cecum and colon, being absent from the vermiform appendix, distal 
sigmoid colon and rectum. 
 
The large intestine’s course starts with a dilation, the cecum, in the right iliac fossa, ascends 
through the right flank (ascending colon), to the right hypochondriac region, where it bends, 
forming the right colic, or hepatic, flexure and crosses the mid upper abdomen (transverse colon) to 
the left hypochondriac region, bending downwards in the left colic, or splenic, flexure and 
descending through the left flank (descending colon) to the left iliac fossa where it forms the 
sigmoid flexure and runs posteroinferiorly into the pelvis (sigmoid colon), forming the rectum and 
ending in the anal canal. The anus is the external opening of the anal canal and is guarded by two 
sphincters: an internal, composed of smooth muscle, and an external, composed of skeletal muscle. 
Arising from the posteromedial wall of the cecum, exists a narrow, vermian tube designated 
vermiform appendix. It contains lymphoid tissue, which tends to decrease towards adulthood, along 
with the size of the appendix itself (Figure 1.2) (Standring, 2011) (Figure 1.2). 
 
 
Figure 1.2 - Overview of the colon (Standring, 2011). 
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A careful comprehension of the vascular supply and lymphatic drainage systems are very important 
to understand the metastization pathways since these are two great conduits that can carry the 
disease to distant organs. Their structure and involvement in the disease must be therefore 
described in some detail (Libutti et al., 2008). 
 
Vascular Supply 
 
The large intestine is supplied by branches of the superior and inferior mesenteric arteries through 
an arching arterial system (Guyton et al., 2005) and drained mainly through the superior and 
inferior mesenteric veins to the portal vein (Figure 1.3 and Figure 1.4) (Standring, 2011). 
 
The cecum is supplied by the ileocolic artery, the last right side branch of the superior mesenteric 
artery, which divides in superior and inferior branches and is drained by the corresponding veins to 
the superior mesenteric vein (Standring, 2011). 
 
Figure 1.3 - Vascular supply of the large intestine (Standring, 2011). 
 
The lower half of the ascending colon receives blood from the ascending branches of the ileocolic 
artery, which anastomoses with the descending branch of the right colic artery. The remaining 
ascending colon and part of the hepatic flexure are supplied by the ascending branch of the right 
colic artery, branch of the superior mesenteric artery, which anastomoses with the right branch of 
the middle colic artery. This section is drained by the corresponding veins to the superior 
mesenteric vein (Standring, 2011). 
 
Parameters for the detection of colorectal cancer recurrences 
 
Introduction  5 
The proximal two thirds of the transverse colon are supplied by the middle colic artery, branch of 
the superior mesenteric artery. The distal third is usually supplied by the ascending branch of the 
left colic artery through the marginal artery, anastomosing with the left branch of the middle colic 
artery. The venous drainage is performed by several tributaries to the middle colic veins, which 
either drain to the superior mesenteric vein or directly to the portal vein (Standring, 2011). 
The blood supply of the descending colon is provided by the left colic artery, branch of the inferior 
mesenteric artery. Its ascending branch supplies the splenic flexure and the descending branch 
provides blood to the remaining descending colon and anastomoses with the sigmoid arteries. This 
section is drained by the corresponding veins to the inferior mesenteric vein (Standring, 2011). 
 
The arterial supply of the sigmoid colon is delivered by the sigmoid arteries, branches of the 
inferior mesenteric arteries. They also supply the lower descending colon, anastomosing with the 
descending branch of the left colic artery (Standring, 2011). 
 
The upper two-thirds of the rectum are supplied by the superior rectal artery, continuation of the 
inferior mesenteric artery, which anastomoses with the sigmoid arteries. The middle third has some 
contribution from the middle rectal artery, branch of the internal iliac artery, when present. The 
distal third is supplied by the ascending branches of the inferior rectal arteries, terminal branches of 
the internal pudendal arteries. The vascular drainage of the rectum is carried out by the rectal 
venous plexus. It has an internal and an external part. The internal drains mainly to the superior 
rectal vein, the start of the inferior mesenteric vein, but connects widely with the external plexus. 
The superior portion of the external also drains to the superior rectal vein, while the middle portion 
is drained by the middle rectal vein and the inferior to the inferior rectal vein, into the internal 
pudendal vein (Standring, 2011). 
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Figure 1.4 - Venous drainage of the large intestine (Standring, 2011). 
 
The blood supply of the anal canal is derived from several arteries: superior rectal artery, inferior 
rectal branch of the pudendal artery and branches of median sacral artery. The venous drainage of 
the upper anal canal is done by the terminal branches of the superior rectal vein into the inferior 
mesenteric vein. The lower anal canal and sphincter are drained through the inferior rectal branch 
of the pudendal vein into the internal iliac vein (Standring, 2011). 
 
Lymphatic drainage 
 
The lymphatic vessels of the large intestine drain to nodes following the course of the main arteries 
that supply the colon – the superior and the inferior mesenteric arteries (Figure 1.5) (Standring, 
2011). 
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Figure 1.5 - Lymphatic drainage of the large intestine (Standring, 2011). 
 
The nodes can be divided into four groups, according to their location: epicolic, the ones closest to 
the intestine, which lie on the serosa, sometimes in the appendices epiploicae;  paracolic, located 
on the borders of the colon;  intermediate colic, positioned along the colic vessels (ileocolic, right, 
middle and left colic, sigmoid and superior rectal arteries) and preterminal colic, which lie 
alongside the main trunks of the superior and inferior mesenteric arteries. These last nodes drain 
into para-aortic nodes at the source of those vessels (Standring, 2011). 
 
The lymphatic drainage of the anal canal is divided between the lymphatics of the rectum (upper 
anal mucosa, internal sphincter and conjoint longitudinal coat) and external inguinal lymph nodes 
(lower anal canal and external anal sphincter) (Standring, 2011). 
 
The knowledge of the lymphatic drainage is of crucial importance to understand the metastatic 
potential of colorectal cancer and influences surgical decisions, based on the location and local 
tissue spread of the tumor (Standring, 2011). 
 
1.1.2. Histology 
 
1.1.2.1. Gastrointestinal tract 
 
The histology of the GI tract has similar traits throughout its different segments. The tract wall is 
formed by four distinct layers: mucosa, submucosa, muscularis externa and serosa (Figure 1.6) 
(Junqueira et al., 2004;Standring, 2011). 
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Figure 1.6 - General histology of the GI tract (adapted from Seeley et al., 2004). 
 
The mucosa is constituted by epithelium, lamina propria and muscularis mucosae. 
 
The submucosa is composed of connective tissue with blood and lymphatic vessels and the 
submucosal (Meissner) nervous plexus. It may also contain glands (restricted to the duodenum) and 
lymphoid tissue (Junqueira et al., 2004;Standring, 2011). 
 
The muscularis externa has external longitudinal and internal circular layers of smooth muscle 
cells. Between these two layers is located the myenteric (Auerbach) nervous plexus (Junqueira et 
al., 2004;Standring, 2011). 
The serosa is referred above as visceral peritoneum and is composed of a layer of simple squamous 
epithelium, covering connective tissue with blood and lymphatic vessels, as well as adipose tissue 
(Junqueira et al., 2004;Standring, 2011). 
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1.1.2.2. Large intestine 
 
Mucosa 
 
Epithelium 
The luminal surface of the large intestine is lined by several types of cells: columnar, mucous, 
microfold, stem and neuroendocrine. These cells are not all evenly distributed. While columnar and 
mucous cells are the most abundant and present through the whole length of the large intestine, 
microfold cells are restricted to the epithelium overlying lymphoid follicles and both stem and 
neuroendocrine cells are mainly located at the base of the intestinal crypts. The crypts, in the large 
intestine, are long, numerous and are located close together (Standring, 2011). 
 
Lamina Propria 
The lamina propria of the large intestine is composed of connective tissue. It contains solitary 
lymphoid follicles, most abundant in the cecum, appendix and rectum, from which originate 
efferent lymphatic vessels (Standring, 2011). 
 
Muscularis Mucosae 
The muscularis mucosae is composed by internal circular and external longitudinal layers of 
smooth muscle cells (Standring, 2011). 
 
Submucosa 
The submucosa of the large intestine is similar to that of the remaining GI tract described above 
(Standring, 2011). 
 
Muscularis externa 
The aggregation of the longitudinal muscle fibers in three bands forms the taeniae coli, leaving 
only a thin layer of longitudinal fibers between them.  The circular fibers form a thick layer in the 
rectum and the internal anal sphincter in the anal canal;  in the cecum and remaining colon, they 
form a thin layer, particularly aggregated in between the sacculations (Standring, 2011). 
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Serosa 
In the large intestine, the visceral peritoneum forms small appendices filled with adipose tissue – 
appendices epiploicae (Junqueira et al., 2004). These are most numerous in the sigmoid and 
transverse colon, but generally absent from the rectum (Standring, 2011). 
 
1.2. COLORECTAL CANCER 
 
Colorectal cancer (CRC) is one of the most common malignancies and has a high mortality rate. It 
is the third more frequently diagnosed neoplasm and the second leading cancer-caused death in the 
United States of America in both men and women (Edwards et al., 2010). In Portugal, the statistics 
are slightly different. Here, cancer of the colon, rectum, rectosigmoid junction and anus is the 
leading cancer-caused death (Estatísticas da Saúde - 2005, 2006). Its death rate in Portugal 
(mainland) is 31.2 per 100000 inhabitants (Risco de Morrer em Portugal 2006 - Volume II, 2006). 
The European data from 1998 to 2002 indicates a death rate of 18.5 and 10.7 per 100000 
inhabitants for man and woman respectively (Zavoral et al., 2009). 
 
The most important demographic factor in the etiology of CRC is age (Libutti et al., 2008), but 
there are other contributing factors such as sedentary life style, diet(Baxter et al., 2007) and 
possibly many others. However, identifying specific agents that influence the risk of developing 
such cancer is a great challenge (Libutti et al., 2008). 
 
Despite the improvements in early detection of CRC that allowed the decrease of the overall CRC 
mortality in the last decade, the incidence has risen in the population under fifty years of age, 
among both men and women (Edwards et al., 2010). 
 
Genetic predisposition has a strong influence in the risk of developing CRC. The involvement of a 
first-degree relative with CRC doubles the risk of harboring the disease and increases the likelihood 
to develop premalignant adenomas (Libutti et al., 2008). 
 
Familial diseases that lead to CRC are also a factor to take into account. Familial Adenomatous 
Polyposis accounts for 1% of all CRC incidence;  100% of the patients who harbor it will evolve 
into CRC if the colon is not completely removed (Libutti et al., 2008). Patients with Hereditary 
Nonpolyposis Colorectal Cancer have an increased risk of 80% and an accelerated rate of 
progression to CRC. The disease accounts for 3% of all CRC. Hamartomatous Polyposis 
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Syndromes contribute to less than 1% of all CRC annually and affects mainly the pediatric and 
adolescent population (Libutti et al., 2008). 
 
1.2.1. Diagnosis 
 
Colorectal cancer, when diagnosed early, has good curative probabilities, but the same is not 
applied to later detections. The overall five-year survival rate among CRC patients is 40-50% 
(Jemal et al., 2006), but the five-year survival rates for localized, regional and distant stages of 
disease are 90, 70 and 12%, respectively (Edwards et al., 2010). Unfortunately, the early diagnosis 
is not enough, since a high rate of patients diagnosed with early stage disease will develop a 
recurrence later. 
 
1.2.1.1. Symptoms 
 
Symptoms and other conditions, reflected in laboratory values, associated with CRC are shown in 
Table 1.2. 
 
Table 1.2 - Symptoms and conditions associated with CRC. Adapted from DeVita, 2008. 
Symptoms  
 Change in bowel habits;  
 Weight loss;  
 Weakness;  
 Hepatomegaly;  
 Jaundice. 
 Lower GI bleeding;  
 Abdominal pain;  
 Change in appetite;  
 
Blood in stools (bright blood, melena or hemoccult positive stool, depending 
on the location and stage of the disease);  
 Adenopathy;  
 Obstructive symptoms. 
Other conditions  
 Electrolyte derangements;  
 Carcinoembryonic antigen elevation. 
 Iron deficiency anemia;  
 Liver function abnormalities;  
 
The examination should include physical exam, patient and family history, laboratory tests, 
computed tomography and colonoscopy. The latter is considered the most sensitive method for 
screening (Libutti et al., 2008) since it allows the visualization of the colon to find intestinal polyps 
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that may either harbor the disease or premalignant formations (adenomas) or find full-fledged 
carcinomas. 
 
1.2.2. Tumor Markers 
 
Tumor markers (TM) are endogenous substances that are found in blood, stools, tumor tissue or 
any other tissue, in an altered state, when a patient develops cancer or some benign conditions. 
They can be produced by the cancer cells themselves or by any other cell in the body in response to 
the disease.  
 
There are different TM for different types of cancer. However, some of them may be altered in 
more than one type and in some benign conditions. Furthermore, some people do not present 
altered levels, especially in the early stages of the disease.  
 
There currently are several biological markers identified for CRC. They can be arranged in three 
categories according to their biological substrate: serum, tissue and feces. Carcinoembryonic 
antigen (CEA), KRAS and Fecal Occult Blood Testing (FOBT) are, respectively, examples from 
these categories.  
 
Carcinoembryonic antigen is a glycoprotein expressed in normal or neoplastic epithelia of the gut, 
liver, lung and breast, among other tissues. Belonging to the immunoglobulin supergene family, 
these molecules play a role in cell adhesion and cell surface recognition. Their expression is also 
correlated with differentiation and architecture of epithelia, colonization for microbial flora, signal 
transduction, interaction with cytoskeleton and they are also present in sweat glands (Metze et al., 
1996). 
 
This marker was described for the first time in 1965 by Gold and Freedman (Gold et al., 1965) and 
has been the target of many studies since then. Nowadays it is recommended as a tool for 
prognosis, postsurgical follow-up and monitoring therapy in advanced disease (Duffy et al., 
2007;Locker et al., 2006). 
 
Carbohydrate Antigen 19-9 (CA 19-9) (also a serum marker) is the second most investigated CRC 
serum marker and was described in 1979 by molecular hybridization techniques (Koprowski et al., 
1979). The use of CA 19-9 is not recommended either by the European Group on Tumor Markers 
(EGTM) (Duffy et al., 2007), the American Society of Clinical Oncology (ASCO) (Locker et al., 
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2006) or the National Comprehensive Cancer Network (NCCN) (Colon Cancer - NCCN, 
2011;Rectal Cancer - NCCN 2011) for diagnosis, prognosis or surveillance. However, several 
authors report that it is useful as an indicator of poor prognosis and metastasis (Barillari et al., 
1992;Chen et al., 2005;Yakabe et al., 2010). Accordingly, the Japanese Society for Cancer of the 
Colon and Rectum (JSCCR) recommends its measurement in combination with CEA during 
postoperative surveillance (Yakabe et al., 2010).  
 
The response markers KRAS and/or BRAF genes are frequently mutated in CRC (Barault et al., 
2008). They are both used to identify patients that will not benefit from therapeutic agents that 
target the epidermal growth factor receptor (EGFR). 
 
FOBT is a common test to detect blood in the stool (Ayham et al., 2009). The problem with this 
marker is the fact that colorectal neoplasms are not the single pathological condition that releases 
blood to the colon/rectum and that bleeding occurs only sporadically in CRC (Ayham et al., 2009). 
 
The ideal tumor marker, apart from being obtained by minimally invasive procedures in any 
location and having an accessible cost, should rise when the smallest neoplastic lesion appears and 
increase only when a tumor is present. It should be produced by all neoplastic cells and its levels 
increase proportionally to tumor extent. Finally, it must be produced by all patients (Fernandes et 
al., 2005). 
 
Since this perfect biological marker does not exist, it is necessary to identify other parameters that, 
when used in combination, compose a more specific and sensitive tool to facilitate the diagnosis 
and the prognosis. 
 
The extensive literature includes a vast number of parameters to manage colorectal cancer. The 
following sections describe the possible use of the ones found most useful or promising in the 
prediction of survival and/or recurrence. 
 
1.3. PARAMETERS RELATED WITH SURVIVAL AND RECURRENCE 
 
It is difficult to accurately stage malignancies before the surgical procedure. Additionally, patients 
with the same CRC cancer stage present different survival periods, making the identification of 
highly predictive prognostic factors of CRC of utmost importance. Several factors, related to the 
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evolution of the tumor and/or the general health status of the patients are possible candidates and 
should be investigated. 
 
The following parameters and their relation with survival and/or recurrence are summarized in 
Figure 1.7 at the end of this section. 
 
1.3.1. Clinicopathological parameters 
 
The UICC - TNM classification divides the patients into groups, according to the invasiveness and 
spread of the disease. It is based in macro and microscopic evaluation of the tumor and imaging 
techniques. The continuous growth of knowledge provides information that further stratifies these 
groups and tailors the therapeutic options for patients with specific characteristics, having a great 
impact on clinical practice.   
 
Of great interest is the accurate identification of the node-negative patients belonging to the high-
risk group that will experience recurrence in five years’ time (Benson et al., 2004) and that may 
benefit from adjuvant therapy, similarly to node-positive patients. This decision has to be weighed 
individually for each patient and is considered in the most recent ESMO guidelines (Labianca et 
al., 2010). These patients may present with one of the following: suboptimal regional lymph node 
sampling; poorly differentiated tumor; lymphovascular invasion; perineural invasion; occlusive or 
perforating tumor and pT4 stage (Labianca et al., 2010). 
 
The clinicopathological examination of tumor specimens’ characteristics probably still has much 
information that can be used to that purpose. Some of these characteristics will be discussed in this 
section. 
 
1.3.1.1. Perineural Invasion 
 
Perineural invasion has been associated with a more aggressive phenotype in other pathologies, like 
head and neck cancer (Liebig et al., 2009). Unfortunately, in CRC, its importance has not yet been 
fully established and it is frequently underreported (Liebig et al., 2009). It has been established that 
a relation with Cancer-specific and Disease-free survival (DFS) exists in node-negative patients 
(Colon Cancer - NCCN, 2011). Therefore, PNI may provide useful information to distinguish stage 
II patients that may benefit from adjuvant therapy (Fujita et al., 2007;Fujita et al., 2003). In 
addition to node-negative patients, Fujita, et al. found that the presence of PNI was also statistically 
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related with DFS for stage III patients with colon cancer (Fujita et al., 2007). However, its use may 
be more limited in node-positive patients than in node-negative. 
 
Results relating PNI with poor tumor differentiation, higher stage and increased metastatic disease 
at time of diagnosis suggest a role in disease progression and in tumor metastasis that has yet to be 
clarified (Liebig et al., 2009). In addition, it is possible that the presence of PNI influences local 
(Fujita et al., 2007) and distant metastatic (Fujita et al., 2007;Quah et al., 2008) recurrences and 
may be used as a predictor for lymph node metastasis (Fujita et al., 2007;Huh et al., 2010). 
 
In conclusion, PNI may offer much more information on staging, prognostic and therapy and it is 
relatively easy to evaluate in the routine pathological examination. Further studies are necessary to 
confirm this data. 
 
1.3.1.2. Extra Nodal Tumor Deposits 
 
Extra nodal tumor deposits are defined as Irregular discrete tumor deposits in pericolic or 
perirectal fat from the leading edge of the tumor and showing no evidence of residual lymph node 
tissue, but within the lymphatic drainage of the primary carcinoma, are considered peritumoral 
deposits or satellite nodules and are not counted as lymph nodes replaced by tumor (Colon Cancer 
- NCCN, 2011). 
 
Puppa et al. (Puppa et al., 2009) investigated three types of deposits that influence the patients’ 
prognosis in CRC differently. Among them, they found that tumor deposits with irregular shape, 
infiltrative appearance, not surrounded by lymphocytes and typically in close association with large 
vessels or nerves had greater impact on the prognosis of stage III patients, taking them near the 
prognosis of stage IV patients. This kind of deposits had already been associated with greater 
impact on survival than lymph node metastases and other types of vascular invasion (Ueno et al., 
2007). 
 
These deposits can be categorized in different ways, which results in different prognostic values 
(Ueno et al., 2007). Nevertheless, they provide valuable information that cannot be disregarded 
during staging and that should be explored as much as possible. 
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1.3.1.3. Inadequate number of lymph nodes examined 
 
The number of lymph nodes has been found to be a prognostic factor for CRC, with a minimum of 
12 nodes to accurately identify stage II cancers (Colon Cancer - NCCN, 2011). 
 
The removal of a large number of lymph nodes may have side-effects, such as lymphedema. An 
alternative could be the use of sentinel lymph node biopsy. However, its use in CRC is still 
experimental (Colon Cancer - NCCN, 2011) and there is a vast number of techniques used in breast 
cancer and melanoma that are not usable or, for the moment, fully adapted to CRC (Bembenek et 
al., 2008). 
 
1.3.1.4. Lymphovascular Invasion 
 
Lymphovascular invasion is considered an independent prognostic factor regardless of cancer stage 
(Harris et al., 2008). It has been associated with a greater risk of lymph node metastases (Huh et 
al., 2010) and the involvement of extramural veins has been related with increased risk of liver 
metastases (Compton et al., 2000). 
 
Although LVI is a parameter with recognized value in the guidelines, there is a great deal of 
variability between the observers (Harris et al., 2008), and while some do not find it  significant as 
an independent factor (Fujita et al., 2003), others show that it is significant in colon cancer, but not 
in rectal (Tsai et al., 2009);  Zlobec et al (Zlobec et al., 2008) finds it significant together with Raf-
1 Kinase Inhibitor Protein to distinguish stage II patients in the high-risk group. These results are in 
accordance with the works of Tsai (Tsai et al., 2008) and Meguerditchian (Meguerditchian et al., 
2005). 
 
Similarly to PNI, LVI is a parameter readily available in the specimen examination that should be 
reported more often and standards should be used in order to assess the correct strength of this 
factor and improve patient care. 
 
1.3.1.5. Response markers 
 
Genetic testing is very useful when it comes to predict response to some chemotherapeutic agents.  
Mutations of the KRAS gene are associated with shorter survival (Lièvre et al., 2006) and 
decreased response to therapeutic agents that target EGFR. Moreover, these mutations are present 
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in about 40% of colorectal cancers (Barault et al., 2008;Richman et al., 2009). Mutation testing of 
codons 12 and 13 of exon 2 of KRAS gene is therefore recommended by the NCCN guidelines for 
colon and rectal cancer (Colon Cancer - NCCN, 2011;Rectal Cancer - NCCN 2011) before therapy 
is initiated in metastatic disease. 
 
KRAS is not the only gene involved in the EGFR signaling pathway. BRAF is also an important 
marker to consider in anti-EGFR therapy, being mutated in <15% of colorectal cancers (Siena et 
al., 2009). Although the mutation of BRAF is less frequent that the mutation of KRAS, the 
presence of wild-type (non-mutated) BRAF is thought to be of utmost importance for anti-EGFR 
therapy (Colon Cancer - NCCN, 2011;Di Nicolantonio et al., 2008). Mutation testing of BRAF 
V600E allele is also recommended by the NCCN guidelines for colon and rectal cancer before 
therapy is initiated in metastatic disease. 
 
1.3.2. Hematological and biochemical parameters 
 
Several biochemical parameters have been evaluated in relation to CRC survival. 
 
Dixon et al. analyzed alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, 
total bilirubin, prothrombin time, mean corpuscular volume, fibrinogen, hematocrit and creatinine. 
Univariate testing identified alkaline phosphatase, aspartate aminotransferase and total bilirubin as 
significantly associated with survival in patients with stage IV colon and rectal adenocarcinoma. 
 
In another study, with patients with Dukes’ A, B or C disease, abnormal liver function test values 
were not found to be statistically significant in univariate testing for survival (Wang et al., 2000). 
In both studies, none of those parameters was found to be statistically significant for survival in 
multivariate analysis (Dixon et al., 2003;Wang et al., 2000). 
 
Despite correlation of hemoglobin levels with survival has been found in some studies, no definite 
conclusions can be drawn as of yet. Low hemoglobin levels have been found to negatively 
influence survival in more than one study. Heys et al. found that relation in univariate analysis, 
although no statistically significant difference between the different Dukes’ categories was found. 
In another study, it was found to be correlated with progression-free and overall survival, as well as 
distant relapse, but not with clinical response (Roldan et al., 2010). Conversely, Gobbi et al. did not 
find it statistically significant for survival in any of the analyses.  
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1.3.2.1. Preoperative Serum Albumin 
 
Cancer patients frequently present low serum albumin levels. These values are related with shorter 
overall survival in CRC, by univariate and/or multivariate analysis (Cengiz et al., 2006;Dixon et 
al., 2003;Heys et al., 1998;Sun et al., 2009) and tend to lower as the disease progresses. The 
decreased levels probably result from an ongoing systemic inflammatory response that translates in 
to a higher demand of aminoacids for acute-phase protein synthesis and immune and anti-oxidant 
defenses (McMillan et al., 2001). The sources for these aminoacids are the serum proteins and the 
skeletal muscle (McMillan et al., 2001). The loss of skeletal muscle will translate in changes in 
body mass and the nutritional deficit will eventually lead to the death of the patient. However, 
being a larger reservoir of protein than the serum, body mass decrease will be noticed much later 
than the changes in serum total proteins (Heys et al., 1998) and, more specifically, in serum 
albumin values (McMillan et al., 2001). 
 
The importance of serum albumin concentrations on CRC management has not yet been fully 
clarified but by the revision of the aforementioned studies its decrease may present as an early sign 
of malignancy and should seize the clinicians’ attention.  
 
1.3.2.2. Serum Glucose 
 
A characteristic related with hyperglycemia, hyperinsulinemia, has substantial information 
indicating that it may play an important role in CRC (Giovannucci, 1995;McKeown-Eyssen, 1994). 
The presence of insulin receptors has been observed in both normal and malignant colorectal cells 
(Wong et al., 1985) and the latter have been shown to express insulin-like growth factors. (Cullen 
et al., 1991) It is not, therefore, strange that the risen insulin values are related with colorectal 
malignancies. The great role that environmental factors like obesity and sedentary lifestyle, as well 
as others that promote insulin production and/or resistance, play in colorectal carcinogenesis is 
another hint that supports this position (Giovannucci, 2001). 
 
In several studies, glycemic load (Franceschi et al., 2001;Michaud et al., 2005), glycemic index 
(Franceschi et al., 2001) or sugar intake (Michaud et al., 2005) have been found related with 
increased CRC risk. However, a meta-analysis by Mulholland et al. (Mulholland et al., 2009) that 
included these studies and ten others, indicated that glycemic load and index intakes are not 
associated with risk of CRC. 
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Some investigators used blood glucose measurements to assess CRC risk. While Nilsen et al. 
(Nilsen et al., 2001) found a positive association in woman and Schoen et al. (Schoen et al., 1999) 
found it without discriminating for gender, Tsushima et al. (Tsushima et al., 2005) did not (for 
either sex). On another study, Trevisan et al. (Trevisan et al., 2001) revealed a relationship between 
high blood glucose and risk of death by CRC. 
 
The study of colorectal adenomas, the stage that precedes CRC, has provided contrasting results. 
While most authors have found a positive relation between blood glucose and the formation of 
adenomas and one that this relation is even stronger between glucose and CRC, which may mean 
that glucose is involved in progression to CRC, Park et al. (Park et al., 2000) found an inverse 
result.  
 
1.3.2.3. Serum CEA Values 
 
Carcinoembryonic antigen is the oldest tumor marker in use for CRC. In addition, it is the only 
parameter that gathers enough consensual information to allow a standardized use. Even though it 
was discovered in 1965, there is still much investigation concerning its use for CRC and some of its 
results will be discussed in this section. 
 
CEA kinetic parameters 
Kim et al.(Kim et al., 2009) found that the CEA clearance via exponential kinetics is significantly 
related with better overall survival and disease-free survival while clearance via randomized 
kinetics is related with worse prognosis. The latter suggests failure of the complete resection of the 
tumor, the existence of micrometastasis or regrowth of the remnant tumors. 
 
The doubling time (CEA-DT) and half-life time (CEA-HL) of CEA have been evaluated as 
predictors of prognosis or metastatic progression in CRC (Ito et al., 2002). 
 
Although the results of Ito et al. show significant correlation between preoperative CEA-DT and 
after-surgery survival, they have limited validity due to postoperative adjuvant chemotherapy and 
re-resection after development of relapse or metastasis. Nevertheless, CEA-DT has been found 
related with the outcome of patients with recurrent CRC in general,(Staab et al., 1982) with liver 
metastasis (Koga et al., 1999;Tanaka et al., 2004) and capable of distinguishing between 
candidates for repeat hepatectomy and those patients at high risk of multiple early recurrences 
(Tanaka et al., 2004). 
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The objective underlying the evaluation of postsurgical CEA-HL was to diagnose overlooked 
metastases. The results indicate that the prolongation of the half-life time might suggest the 
existence of metastases earlier and more rigorously than the increase of CEA level in the 
postoperative period after a prolonged regression. In addition, the evaluation of postoperative CEA 
regression gradient might be helpful to identify patients who are undergoing complete or partial 
response. 
 
Preoperative CEA values 
The need for identifying populations who benefit from regular postoperative CEA monitoring is 
related to the low percentage of patients that present elevated CEA levels prior to the recurrence 
(Park et al., 2009). 
 
Park et al. (Park et al., 2009) found that only a reduced number of patients with normal 
preoperative CEA levels would present with elevated CEA levels before the diagnoses of a 
recurrence. Conversely, a greater percentage of the patients who presented with high CEA levels 
before the surgery, presented also with elevated levels before the diagnosis of the recurrence. This 
data corroborates the indication of the guideline of the American Society of Clinical Oncology 
(ASCO) (Locker et al., 2006) of using preoperative CEA levels to assess its utility in the surgery 
follow-up phase. 
 
The ASCO guideline (Locker et al., 2006) recommends the use of preoperative CEA testing  for 
assisting in staging and surgical treatment planning, providing prognostic information and aiding in 
assessing its utility for postoperative surveillance. In fact, preoperative CEA values have been 
recognized as a prognostic factor for CRC after curative surgery by several authors (Harrison et al., 
1997;Park et al., 2009;Park et al., 2005;Sun et al., 2009;Takagawa et al., 2008;Wang et al., 2000). 
However, there is not a consensus about which value (cut-off) should be used to distinguish 
between higher-risk and lower-risk populations.  
 
Whereas some authors use the standard cut-off value of 5 ng/mL (although the one described in the 
literature as the normal value of carcinoembryonic antigen in a healthy person is 2.5 ng/mL and 5.0 
ng/mL in smokers (Dugdale, 2009a)) and based their investigations about preoperative CEA levels 
on that value (Filiz et al., 2009;Wang et al., 2000), others focused on finding the value that 
separates the different populations with greater accuracy. While Park et al. (Park et al., 2005) 
found that patients who presented preoperative levels above 3.0 ng/mL, were at higher risk of 
developing a recurrence after the curative surgery, Takagawa et al. identified 10.0 ng/mL as the 
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optimal cut-off value. More investigation is necessary to establish a reference value to use in the 
clinic. 
 
Patients with higher preoperative CEA values, present often with greater tumor diameter, lymphatic 
invasion, higher TNM stage and perineural invasion (Table 1.3). 
 
These factors are measures of the development of the tumor, presumably, because a more 
advanced, larger and possibly metastasized tumor produces more CEA. 
 
Table 1.3 - Clinicopathological factors related with high preoperative CEA values 
Clinicopathological factor References 
Tumor diameter (Takagawa et al., 2008) 
Lymphatic invasion (Filiz et al., 2009;Takagawa et al., 2008) 
UICC - TNM stage 
(Filiz et al., 2009;Park et al., 2009;Park et al., 
2005;Takagawa et al., 2008) 
Perineural invasion 
(Filiz et al., 2009;Park et al., 2009;Takagawa et 
al., 2008) 
 
On the other hand, several other characteristics have been described as not being associated with 
elevated preoperative CEA, like vascular invasion (Park et al., 2009;Takagawa et al., 2008), tumor 
location (colon/rectum) (Filiz et al., 2009;Park et al., 2009;Takagawa et al., 2008) and histologic 
type (Filiz et al., 2009;Park et al., 2009;Park et al., 2005;Takagawa et al., 2008). The reason why 
vascular invasion, which also reflects development of the tumor, is not related with preoperative 
CEA levels is not clear. From the association established above between CEA values and the tumor 
characteristics, a clinician may be able to infer about the depth of invasion, tumor size and 
metastases. 
 
Postoperative CEA values 
Intensive postoperative follow-up routines, which include several of the following procedures - 
clinical assessment, blood tests, CEA levels, chest radiograph, fecal occult blood test, liver 
ultrasound, computerized tomography, colonoscopy, sigmoidoscopy, barium enema, and others - 
have been established as improvers of survival and/or predictors of recurrence (Renehan et al., 
2002;Rodriguez-Moranta et al., 2006;Tjandra et al., 2007;Wanebo et al., 1978). These are valuable 
procedures because the intensive follow-up enables an earlier detection of recurrences, allowing 
more effective treatment or surgery. 
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The ASCO guidelines recommend postoperative CEA testing every three months for at least three 
years after diagnosis when the patient (with stage II or III disease) is a candidate for surgery or 
systemic therapy. If elevated CEA values are found and confirmed by retesting, further evaluation 
is performed. 
 
Although postoperative CEA values have been recognized as predictors of recurrences (Filiz et al., 
2009;McCall et al., 1994;Rodriguez-Moranta et al., 2006;Tjandra et al., 2007;Tsai et al., 
2009;Wanebo et al., 1978;Watine et al., 2001), these are not always preceded of a marked rise on 
CEA level. This happens for various reasons, and while some of them are probably yet to be 
discovered, others are already known such as the primitive tumor stage and location, as well as the 
location of the recurrence. The latter is frequently related with the location of the primitive tumor 
as will be discussed below. 
 
When considering tumor stage, Hara et al. (Hara et al., 2010) found that the elevation of CEA in 
patients with stage II disease, unlike in those with stage III, does not have a high probability of 
predicting recurrence due to its high false-positive rate. These results are in accordance with those 
obtained by Park et al. (Park et al., 2006), who found no differences between high and low 
perioperative CEA values relatively to survival in patients with stage II CRC. 
 
As far as the recurrence location is concerned, hepatic metastases and disseminated disease are the 
ones who elicit the greatest elevations in CEA values (Wanebo et al., 1978). Local or pelvic 
recurrences frequently present normal or just slightly elevated CEA values (Wanebo et al., 1978). 
 
On the relationship between the recurrence location and the primitive tumor location, the liver is 
the most common location for recurrences of CRC (Hara et al., 2010;Tsai et al., 2009). Henceforth, 
if a patient presents with elevated CEA values, he has a strong possibility of harbouring a liver 
metastasis. On the other hand, local recurrences are more common in early relapses of rectal cancer 
(Tsai et al., 2009) and, since local recurrences do not usually provoke brisk CEA changes, these 
may pass unnoticed if an intensive follow-up strategy is not applied (Rodriguez-Moranta et al., 
2006). The same follow-up strategy applies to patients with stage II tumors, who frequently 
develop undetected recurrences, but not to those with stage III. The study by Rodriguez-Moranta et 
al. found that patients with stage III cancer did not benefit from the intensive strategy in the first 
two years, presumably because CEA presents a much lower rate of false positive results in this 
cancer stage (Hara et al., 2010) 
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Figure 1.7 - Relations of CRC prognostic factors with tumor recurrence and patient survival. 
Perineural Invasion (Colon Cancer - NCCN, 2011;Rectal Cancer - NCCN 2011); Extra Nodal Tumor Deposits 
(Colon Cancer - NCCN, 2011;Rectal Cancer - NCCN 2011); Lymphovascular Invasion (Fujita et al., 2003;Tsai et 
al., 2009) No. of Examined Lymph Nodes (Colon Cancer - NCCN, 2011); Hemoglobin (Heys et al., 1998;Roldan et 
al., 2010); Preoperative Albumin (Cengiz et al., 2006;Dixon et al., 2003;Heys et al., 1998;Sun et al., 2009); CEA 
Clearance (Kim et al., 2009); CEA Doubling-time (Ito et al., 2002;Koga et al., 1999;Staab et al., 1982;Tanaka et al., 
2004); Pre- and Postoperative CEA (Colon Cancer - NCCN, 2011;Locker et al., 2006;Rectal Cancer - NCCN 
2011). 
* There is still no consensus on the value of hemoglobin for CRC prognostic assessment (Section 1.3.2). It is 
included in this illustration because several studies point to some relation with survival and/or recurrence and it 
may yet be proven useful. 
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CHAPTER 2: AIM 
 
The aims of this dissertation are (a) to identify biochemical or clinicopathological parameters of 
patients with colorectal cancer, who have undergone curative surgery, that allow an earlier 
detection of recurrence, and (b) carry out a clinical investigation with non-standardized registries, 
while using retrospective data, gathered during the daily clinical practice. 
 
To achieve it, we proposed to: 
a) Gather retrospective patient data systematically;  
b) Analyze the data with conventional statistical tools in univariant and multivariant 
methodologies. 
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CHAPTER 3: METHODS 
 
3.1. ADMINISTRATIVE PROCESS  
 
This project was submitted to the approval by the Infante D. Pedro E.P.E Hospital (IDPH) and 
University of Aveiro Joint Commission on the 28
th
 of September of 2010. It was approved on the 
15
th
 of October of the same year and submitted to approval by the Administration of IDPH and the 
Ethics Committee of the same institution on the 19
th
 of October of 2010. The approval was 
obtained on the 22
nd
 of November of 2010. 
 
3.2. DATA COLLECTION 
 
From the period between 2005 and 2010, 442 electronic patient files were screened for inclusion in 
the study. The ones that appeared to fill the inclusion criteria were requested to the archive because 
the electronic files did not have all of the desired information.  
 
Retrospective clinical information was gathered for 190 patients from 2005 to 2010 with diagnosis 
of colorectal cancer at the Oncology and Surgery Services of IDPH according to the following 
inclusion criteria:  
 Histologically confirmed diagnosis of colorectal cancer;  
 Candidate for curative surgery;  
 No perioperative mortality. 
 
Only 153 patients were included in our analysis due to the restriction of our exclusion criteria 
(Figure 3.1): 
 Concomitant non-related cancer;  
 Lack of biochemical or clinical data in the file;  
 Lack of curative surgery;  
 Lack of free-of-disease period;  
 Wrong diagnosis. 
 
The following data was systematically collected from both physical and electronic files of each 
patient to excel sheets: 
 Biochemical data  
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o Liver function tests;  
o Renal function tests;  
o Carcinoembryonic Antigen (CEA);  
o Carbohydrate antigen 19-9 (CA19.9);  
o Serum proteins;  
o Glucose;  
o Cholesterol and triglycerides;  
o Hemoglobin;  
o Hematocrit;  
o Complete blood count. 
 
 Clinicopathological data 
o Tumor Grade;  
o pTNM staging;  
o Lymphatic invasion and embolization;  
o Vascular invasion and embolization;  
o Perineural invasion;  
o Venous invasion;  
 
 Clinical data 
o Date of surgery;  
o Date of death;  
o Date and place of recurrence;  
o Chemotherapy dates and medication;  
o Clinical history. 
 
 Demographic data 
o Age;  
o Sex. 
 
Besides the 37 patients excluded by the criteria, 2 more were removed from some analyses along 
the study for lack of data. (Figure 3.1). 
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Figure 3.1 - Patient selection throughout the study. 
 
The data was further separated into pre- and post-surgical periods. In the post-surgical period, 153 
patients remained – being cut down to 151 throughout the study, while in the pre-surgical, only 107 
were present in the end, when this segment was analyzed.  
  
Data collected from 
patients 
n = 190 
Patients included in the 
descriptive analysis and 
correlation tests 
n = 153 
Excluded n = 37 
• Concomitant non-related cancer n = 7 
• Lack of biochemical or clinical data in the file n = 10 
• Lack of curative surgery n = 7 
• Lack of free-of-disease period n = 9 
• Wrong diagnosis n = 4 
  
  
Patients included in the 
exploratory analysis 
n = 152 
Excluded n = 1 
• Patient without sufficient data before recurrence  
Excluded n = 1 
• Patient with missing recurrence data 
Patients included in the 
prognostic factor analysis 
n = 151 
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3.3. STATISTICS 
 
Preliminary descriptive statistics were obtained for all variables. Since they revealed that most 
variables did not follow a normal distribution, Spearman Rank Correlation test was used to assess 
the correlation between all the biochemical parameters and the tumor markers CEA and CA 19-9. 
 
The data used in this study comprised several measurements of the same parameters for each 
patient, with a variable number of measurements. These measurements were scattered along the 
entire follow-up of the patient with a very irregular distribution. Henceforth, in order to capture a 
value that reflected the mean value, while accounting for the different time lapses between the 
measurements, the area under the curve was calculated for each parameter, with a minimum of two 
measurements, using the following formula, in which A1, A2, A3 and A4 are the areas of the 
trapezoids that build the concentration curve (Figure 3.2): 
 
 
    
              
     
 
 
Figure 3.2 - Example of the calculation of the biochemical parameter’s area under the curve. t1 is the 
concentration of the first measurement after the resective surgery and t2 is the last measurement of that 
parameter. 
 
With the AUC calculated for all the parameters, an exploratory analysis of parameters related with 
recurrence was conducted. 
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Chi-square and Fischer exact test were used to analyze the distribution of the clinicopathological 
characteristics of the patients across subgroups of patients, with and without recurrence and the 
Mann-Whitney U test was used to compare the distribution of the biochemical parameters across 
the subgroups of patients according to recurrence status. 
  
In order to determine the parameters that influenced cancer recurrence the most, three tools were 
used: The area under the Receiver Operating Characteristic (ROC) curves, to determine the 
parameters that best predicted the recurrence event and their cut-off with the best discrimination 
potential, Univariate Cox Proportional Hazards Model, to assess the risk of recurrence associated 
with each parameter and Multivariate Cox Proportional Hazards Model to evaluate the contribution 
of each parameter when analyzed in combination with others to recurrent disease prediction.  
 
The pre-surgical data was the last to be analyzed. The same methods were used to test for 
prediction capability and associated risk. 
   
The software used for the statistical analysis was IBM SPSS Statistics Base 17.0 for Windows
®
 by 
IBM, New York, U.S.A. for most analyses, with the exception of the calculation of cut-offs, in 
which MATLAB
®
 version 7.4.0 (R2007a) by MathWorks, Natick, Massachusetts, U.S.A. was 
used. Results with a p-value under 0.05 were considered significant. 
 
3.4. STUDY DESIGN 
 
 
Figure 3.3 - Study design and schedule 
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CHAPTER 4: RESULTS 
 
4.1. GENERAL DESCRIPTIVE STATISTICS 
 
At the time of diagnosis, the mean age was found to be 67.95 (40 – 87;  SE = 0.847) years with a 
mean time to recurrence of 21.12 (5.63 – 42.83;  SE = 1.94) months. According to TNM Stage, six 
(3.9%) patients had stage 0 disease – stage with tumor in situ, twenty-four (15.7%) had stage I, 
fifty-eight (37.9%) had stage II, forty (26.1%) had stage III, six (3.9%) had stage IV and in 
nineteen patients (12.4%) this information was missing. Fifty-five patients (35.9%) had grade I 
tumors, fifty-eight (37.9%) had grade II, twenty-four (15.7%) had grade III, one (0.7%) had grade 
IV and this information was missing in 15 (9.8%) patients. By the end of the data retrieval period, 
twenty-eight patients (18.3%) had experienced recurrence, with only one (0.7%) patient lacking 
this information. The remaining one hundred and twenty-four patients (81%) did not experience 
such an event. Also, by the end of that same period, six patients (3.9%) had deceased and thirteen 
(8.5%) lacked that information. The remaining one hundred and thirty-four (87.6%) were still alive. 
Among those who had deceased, the mean survival time was 31.4 (19.3 – 36.6;  SE = 2.77) months 
(Table 4.1).  
 
Table 4.1 - Patient characteristics and clinicopathological parameters 
Parameter Patient count (%) n=153 
Gender  
 Feminine 69 (45.1) 
 Masculine 84 (54.9) 
Patient Final State  
 Alive 134 (87.6) 
 Deceased 6 (3.9) 
 Missing 13 (8.5) 
TNM 
 
 
0 6 (3.9) 
 
I 24 (15.7) 
 
II 58 (37.9) 
 
III 40 (26.1) 
 
IV 6 (3.9) 
 
Missing 19 (12.4) 
Recurrence 
 
 
No 124 (81) 
 
Yes 28 (18.3) 
 
Missing 1 (0.7) 
Recurrence Location  
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Parameter Patient count (%) n=153 
 Hepatic 16 (57.1) 
 Pulmonary 4 (14.3) 
 Local 5 (17.9) 
 Uterine 1 (3.6) 
 Peritoneal 1 (3.6) 
 Ovaric 1 (3.6) 
Tumor Location 
 
 
Cecum 18 (11.8) 
 
Ascending Colon 6 (3.9) 
 
Hepatic Flexure 12 (7.8) 
 
Transverse Colon 4 (2.6) 
 
Splenic Flexure 5 (3.3) 
 
Descending Colon 6 (3.9) 
 
Sigmoid Colon 54 (35.3) 
 
Rectosigmoid Junction 8 (5.2) 
 
Rectum 38 (24.8) 
 
Missing 2 (1.3) 
Tumor Grade 
 
 
1 55 (35.9) 
 
2 58 (37.9) 
 
3 24 (15.7) 
 
4 1 (0.7) 
 
Missing 15 (9.8) 
Number of Examined 
Nodes  
 
< 12 86 (56.2) 
 
≥ 12 46 (30.1) 
 
Missing 21 (13.7) 
Vascular Embolization 
 
 
No 1 (0.7) 
 
Yes 1 (0.7) 
 
Missing 151 (98.7) 
Vascular Invasion 
 
 
No 59 (38.6) 
 
Yes 5 (3.3) 
 
Missing 89 (58.2) 
Lymphatic Embolization 
 
 
No 3 (2) 
 
Yes 3 (2) 
 
Missing 147 (96.1) 
Lymphatic Invasion 
 
 
No 24 (15.7) 
 
Yes 11 (7.2) 
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Parameter Patient count (%) n=153 
 
Missing 118 (77.1) 
Venous Invasion 
 
 
No 7 (4.6) 
 
Yes 9 (5.9) 
 
Missing 137 (89.5) 
Perineural Invasion 
 
 
No 13 (8.5) 
 
Yes 8 (5.2) 
 
Missing 132 (86.3) 
 
The clinicopathological parameters that characterized the growth of the tumor into nearby vessels 
and nerves: vascular and lymphatic embolization and invasion and perineural invasion all have 
missing data over 50% and/or a very uneven distribution of data (Table 4.1). 
 
From a total of 153 patients, there are 2995 entries in the biochemical database. The descriptive 
statistics of each parameter that is part of that database are presented in Table 4.2. 
 
Table 4.2 - Descriptive statistics of biochemical data. 
 n    
 Valid Missing Median Minimum Maximum 
Erythrocytes 2879 116 4.2 1.8 6.5 
Hemoglobin 2879 116 12.4 5.4 43.6 
Hematocrit 2879 116 37.6 10.1 96.2 
Mean Corpuscular Volume 2878 117 91.0 29.8 121.0 
Mean Corpuscular Hemoglobin 2878 117 30.1 15.8 40.8 
MCHC 2877 118 32.9 25.4 90.8 
RDW 2812 183 13.7 9.9 31.5 
Total White Blood Cells 2877 118 6.3 0.3 52.4 
Neutrophils 2872 123 3.9 0.0 46.7 
Eosinophils 2869 126 0.1 0.0 2.1 
Basophils 2870 125 0.0 0.0 1.0 
Lymphocytes 2871 124 1.5 0.0 11.1 
Monocytes 2870 125 0.4 0.0 9.8 
Platelets 2823 172 220.0 6.0 1291.0 
Erythrocyte Sedimentation Rate 281 2714 20.0 2.0 128.0 
Prothrombin Time 917 2078 12.1 9.6 53.6 
International Normalized Ratio 915 2080 1.0 0.0 4.8 
Thromboplastin Time 830 2165 28.2 12.4 155.0 
Fibrinogen 30 2965 533.5 26.0 1149.0 
D-Dimers 43 2952 362.0 76.0 2313.0 
Glucose 2471 524 106.6 44.0 494.0 
Glycated Hemoglobin 46 2949 6.9 4.4 63.1 
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 n    
 Valid Missing Median Minimum Maximum 
Blood Urea Nitrogen 2434 561 36.0 0.8 261.7 
Creatinine 2449 546 0.9 0.2 60.4 
Sodium 2369 626 139.3 99.0 170.1 
Potassium 2368 627 4.3 2.1 6.5 
Chloride 2358 637 104.0 76.0 139.0 
Calcium 793 2202 8.8 3.1 10.7 
Phosphorus 371 2624 2.8 0.5 10.1 
Magnesium 546 2449 2.0 1.0 4.2 
Creatine Phosphokinase 203 2792 66.0 8.0 1997.0 
Creatine Kinase-MB 89 2906 14.0 0.0 560.0 
Troponin 79 2916 0.2 0.0 49.0 
Myoglobin 59 2936 43.0 10.0 728.0 
Aspartate Aminotransferase 1866 1129 21.0 6.0 1042.0 
Alanine Aminotransferase 1843 1152 28.0 3.0 827.0 
Lactate Dehydrogenase 1503 1492 191.0 32.0 2799.0 
Bilirubin – Total 1385 1610 0.6 0.1 10.0 
Bilirubin – Direct 1260 1735 0.1 0.0 5.7 
Bilirubin – Indirect 1259 1736 0.5 0.0 4.3 
Alkaline Phosphatase 1545 1450 89.0 25.0 2037.0 
Gamma-Glutamyltransferase 1330 1665 35.0 4.0 1336.0 
C-Reactive Protein 632 2363 2.7 0.0 44.0 
Total Proteins 532 2463 7.0 2.7 8.6 
Albumin 597 2398 3.8 0.7 5.2 
Uric Acid 325 2670 5.0 0.0 10.3 
Cholesterol – Total 261 2734 198.0 7.0 371.0 
Cholesterol – HDL 227 2768 47.0 6.9 271.0 
Cholesterol – LDL 195 2800 127.0 8.0 253.0 
Triglycerides 239 2756 111.0 32.0 527.0 
Amylase 182 2813 49.5 8.0 1123.0 
Lipase 176 2819 53.0 1.0 4240.0 
Iron 159 2836 70.8 8.0 361.0 
Transferrin 79 2916 228.0 40.0 711.0 
Transferrin Saturation 59 2936 21.4 0.2 125.4 
Ferritin 125 2870 50.0 4.0 1253.0 
Vitamin B-12 15 2980 390.0 277.0 751.0 
Folic Acid 16 2979 9.3 3.3 33.4 
Alpha-Fetoprotein 185 2810 1.9 0.9 20.5 
CA 15-3 35 2960 26.0 7.0 1141.2 
CEA 1139 1856 1.4 0.0 823.0 
CA 125 61 2934 5.5 0.5 163.0 
CA 19-9 1092 1903 10.8 1.2 462.9 
PSA 127 2868 1.0 0.1 4172.0 
PSA – Free 29 2966 0.2 0.1 11.9 
T3 22 2973 21.3 1.3 264.0 
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 n    
 Valid Missing Median Minimum Maximum 
T3 – Free 52 2943 3.0 1.1 186.0 
T4 21 2974 7.6 4.4 104.8 
T4 – Free 56 2939 1.2 0.5 15.1 
Thyroid-Stimulating Hormone 81 2914 1.7 0.0 82.8 
Follicle-Stimulating Hormone 1 2994 51.4 51.4 51.4 
Luteinizing Hormone 1 2994 25.7 25.7 25.7 
 
The variables that presented a number of entries (n) under 100 were excluded from the following 
analyses since they individually represent under 5% of the total entries and have not been measured 
in most individuals. Those variables were Fibrinogen (n = 30), D-Dimers (n = 43), Glycated 
Hemoglobin (n = 46), Creatine Kinase-MB (n = 89), Troponin (n = 79), Myoglobin (n = 59), 
Transferrin (n = 79), Transferrin Saturation (n = 59), Vitamin B-12 (n = 15), Folic Acid (n = 16), 
CA 15-3 (n = 35), CA 125 (n = 61), PSA – Free (n = 29), T3 (n = 22), T3 – Free (n = 52), T4 (n = 
21), T4 – Free (n = 56), Thyroid-Stimulating Hormone (n = 81), Follicle-Stimulating Hormone (n = 
1) and Luteinizing Hormone (n = 1). 
 
Most parameters do not follow a normal data distribution. Only Erythrocytes, Hemoglobin, 
Hematocrit, Fibrinogen, D-dimers, Uric Acid, Total Cholesterol, LDL - Cholesterol, Iron, 
Transferrin, Transferrin Saturation, Vitamin B-12, Folic Acid and T3  presented a p-value > 0,05 in 
the Kolmogorov-Smirnov Test. Henceforth, non-parametric methods were used to further analyze 
the data. 
 
4.2. POST-SURGICAL DATA ANALYSIS 
 
The descriptive statistics of this section of the data are presented in Appendix, Table I-1. 
 
The first step of the exploratory analysis of the post-surgical data was the investigation of relations 
between the biochemical parameters and the two tumor markers CEA and CA 19-9. 
 
Since most parameters do not follow a normal distribution, Spearman Rank Correlation Test was 
used. It revealed that, besides being correlated with each other, the values of Lactate 
Dehydrogenase, Gamma-GT, C-Reactive Protein, Total Cholesterol, LDL Cholesterol, 
Triglycerides and Ferritin are significantly correlated with the values of either one or both the 
tumor markers (Table 4.3). Complete correlation results can be found in Appendix I, Table I-2. 
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Table 4.3 - Correlation coefficient of biochemical variables with CEA and CA 19-9. 
 Spearman Correlation Coefficient 
 CEA CA 19-9 
CEA --- 0.281 
CA 19-9 0.281 --- 
Lactate Dehydrogenase 0.356 0.179 
Gamma-GT --- 0.284 
C-Reactive Protein 0.294 --- 
Cholesterol – Total 0.350 --- 
Cholesterol - LDL 0.407 --- 
Triglycerides 0.287 0.382 
Ferritin --- 0.317 
Only statistically significant results are presented 
 
We can observe that most of the parameters that correlate with CEA and CA 19-9 variations are 
related with inflammatory response: ESR and C-Reactive Protein; and liver function: AST, ALT, 
LDH, ALP, Gamma-GT, Cholesterol and Triglycerides. 
 
The biochemical variables’ distributions were tested for differences between the groups of patients 
with and without recurrence. The results that gathered both statistical significance and 
physiological interest are shown in Table 4.4 and complete distribution statistics across recurrence 
groups can be found in Appendix I, Table I-3. 
 
Table 4.4 - Mann-Whitney U tests of biochemical variables across sub-groups of patients with and without 
recurrence. 
 Recurrence 
p-value 
No Yes 
Total White Blood Cells 124 28 0.022 
Glucose 124 28 0.010 
Aspartate Aminotransferase 110 28 0.010 
Lactate Dehydrogenase 102 28 <0.001 
Alkaline Phosphatase 105 28 0.014 
Gamma-GT 99 26 0.048 
C-Reactive Protein 51 19 0.031 
Albumin 60 21 0.034 
CEA 113 23 <0.001 
CA 19-9 114 23 <0.001 
Only statistically significant results are presented. 
 
That same analysis between the groups of patients alive and deceased would have been of interest. 
However, the low number of deceased patients – six – hindered that possibility.  
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An analysis of the clinicopathological parameters against tumor recurrence was impeded by the 
low frequency in those items. Even when Fischer Exact Test was applied, the differences were not 
significant (Table 4.5).  
 
Table 4.5 - Chi-square tests of clinicopathological parameters versus recurrence. 
 p-value 
Vascular Invasion 0.578 
Lymphatic Invasion 0.580 
Perineural Invasion 0.400 
Venous Invasion 0.308 
 
For Tumor Grade, TNM Stage and Tumor Location the percentage of cells with expected counts 
less than 5 were 37.5, 50 and 25% respectively. Therefore, the Chi-square test cannot be applied 
and no data can be obtained for those parameters. 
 
The only clinicopathological parameter that presented a sufficiently high frequency to provide 
relevant results in both groups, after crossed with tumor recurrence, was the Number of Examined 
Nodes. However, the results do not reach statistical significance although they come close to it, 
indicating that, as suggested in the current guidelines (Colon Cancer - NCCN, 2011;Rectal Cancer - 
NCCN 2011), under-sampling of lymphatic nodes poses a risk for CRC patients (Table 4.6). 
 
Table 4.6 - Relation of Number of Examined Nodes with Recurrence. (No., Number)  
 Recurrence 
Total χ
 2
 p-value 
No Yes 
No. of Examined Nodes 
< 12 64 21 85 
3,592 0,058 
≥ 12 41 5 46 
Total 105 26 131   
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4.2.1. Prognostic factors for recurrence 
 
For this analysis, the AUC of each parameter was recalculated, considering only the period 
between the surgery and the recurrence, for the patients who experienced it and between the 
surgery and the end of follow-up for those who did not. 
 
The prognostic factor analysis can be divided in 4 steps: 
1. Correlation analysis of parameters with recurrence;  
2. ROC curve analysis of each of the parameters and determination of the ideal cut-offs;  
3. Univariate Cox regressions;  
4. Multivariate Cox regressions. 
 
The main struggle in this analysis is related with the low number of events – the recurrences (n = 
27) and, additionally, the even lower number of patients with both the desired parameters and 
recurrence (Table 4.7).  
 
Table 4.7 - Number and percentage of patients with recurrence for each of the analyzed parameters. 
 
Recurrence 
Yes Total 
CEA 15 (11.7%) 128 
CA 19-9 15 (11.6%) 129 
Total White Blood Cells 27 (17.9%) 151 
Glucose 26 (17.3%) 150 
Lactate Dehydrogenase 20 (16.4%) 122 
C-Reactive Protein 10 (16.4%) 61 
Albumin 11 (15.5%) 71 
Aspartate Aminotransferase 22 (16.7%) 132 
Alkaline Phosphatase 22 (17.3%) 127 
Gamma-GT 14 (12.4%) 113 
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Correlations 
Table 4.8 - Correlations of the selected biochemical parameters with the occurrence of cancer recurrence. 
 Correlation Coefficient p-value 
CEA 0.360 <0.0001 
CA 19-9 0.248 0.005 
Total White Blood Cells 0.268 0.001 
Glucose 0.182 0.026 
Lactate Dehydrogenase 0.239 0.008 
C-Reactive Protein 0.224 0.083 
Albumin 0.105 0.382 
Aspartate Aminotransferase 0.096 0.272 
Alkaline Phosphatase 0.006 0.950 
Gamma-GT 0.040 0.671 
 
This first step (Table 4.8), shows that only CEA, CA 19-9, TWBC, Glucose and LDH are 
correlated with recurrence, by only discarding the very low coefficient values and the not 
statistically significant. It does not provide specific information on the utility of each parameter as a 
predictor of recurrence but hints which may be useful. The next step confirmed these results. 
 
Receiver Operating Characteristic Curve Analysis 
The area under the ROC curve was calculated to determine the best value (cut-off) to trigger an 
alert of recurrence for each parameter. 
 
From the calculations of sensitivity, specificity and accuracy for several cut-offs, the predictive 
capability and best cut-off were found for each parameter. The ones that did not reveal statistical 
significance were excluded from the next step. 
 
Table 4.9 - Area under the ROC curve, best cut-off, sensitivity, specificity and accuracy of the selected parameters 
for predicting cancer recurrence. 
 ROC AUC p-value Cut-off Sensitivity Specificity Accuracy 
CEA 0.823 < 0.0001 3.4 ng/mL 0.533 0.929 0.883 
CA 19-9 0.724 0.005 14.6 ng/mL 0.533 0.746 0.721 
TWBC 0.702 0.001 6.8x10
3
/µL 0.519 0.677 0.649 
Glucose 0.639 0.026 119.5 mg/dL 0.500 0.726 0.687 
LDH 0.686 0.009 205.8 U/L 0.500 0.686 0.687 
CRP 0.675 0.080 ---  --- --- 
Albumin 0.416 0.378 ---  --- --- 
AST 0.575 0.270 ---  --- --- 
ALP 0.504 0.949 ---  --- --- 
Gamma-GT 0.465 0.669 ---  --- --- 
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Although the traditional approach is to find the value that makes the best balance of specificity and 
sensitivity, due to the low number of events available, we considered the best cut-off for each 
parameter as the one with best accuracy after 50% of the events (recurrence) had been detected. 
That explains the sensitivity near 0.5 of all the parameters’ cut-offs in Table 4.9 since the value 
with greater accuracy after 50% of the recurrences had been detected was usually that same value. 
 
On this analysis, five factors were identified with prognostic capability: CEA, CA 19-9, Total 
TWBC, Glucose and LDH (Table 4.9) 
 
Gamma-GT predictive capability was also calculated only for hepatic recurrences, not reaching 
statistical significance with p = 0.840. 
 
Figure 4.1 - ROC Curves of the selected parameters with predictive capability. 
 
The curve of Carcinoembryonic antigen clearly stands out from the remaining parameters in Figure 
4.1. The closest a curve gets to the top left corner, the better predictive properties that parameter 
possesses because it combines the highest specificity and sensibility. 
 
Univariate Cox regressions 
The individual predictive capability of each parameter was assessed with univariate Cox 
regressions. 
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Table 4.10 - Univariate analysis with Cox proportional hazards model of the parameters with predictive capability 
of tumor recurrence. 
 p-value Hazard Ratio (95% CI) 
CEA (>3.4 ng/mL) <0.0001 8.494 (3.096 – 23.506) 
CA 19-9 (>14.6 ng/mL) 0.038 2.938 (1.064 – 8.112) 
TWBC (>6.8x10
3
/µL) 0.032 2.296 (1.075 – 4.907) 
Glucose (>119.5 mg/dL) 0.021 2.478 (1.144 – 5.367) 
Lactate Dehydrogenase (>205.8 U/L) 0.049 2.424 (1.004 – 5.852) 
 
All parameters analyzed by the Cox proportional hazards model in this step provided significant 
results (Table 4.10). The difference between CEA values under and over 3.4 ng/mL is the most 
powerful predictor of recurrence in this analysis, followed by CA 19-9, although the latter is much 
closer to the remaining parameters. The remaining parameters appear to have similar prognostic 
properties. 
 
Multivariate Cox regressions 
After introducing all the factors with univariate p < 0.05 in a Cox proportional hazards model, 
Glucose and CEA were the only parameters identified as independent prognostic factors of CRC 
recurrence (Table 4.11) with additional risks of 3.990 and 5.198, respectively. 
 
Table 4.11 - Multivariate analysis with Cox proportional hazards model of the prognostic factors for tumor 
recurrence. 
 p-value Hazard Ratio (HR) 95% CI 
CEA (>3.4 ng/mL) 0.012 5.198 1.429 – 18.903 
Glucose (>119.5 mg/dL) 0.029 3.990 1.149 – 13.857 
Lactate Dehydrogenase (>205.8 U/L) 0.083 --- --- 
TWBC (>6.8x10
3
/µL) 0.390 --- --- 
CA 19-9 (>14.5 ng/mL) 0.675 --- --- 
 
Since CEA was the strongest predictor in the analysis, it was removed to check for other 
parameters that might stand out when it was not present. 
 
Table 4.12 - Multivariate analysis with Cox proportional hazards model of Glucose, TWBC, LDH and CA 19-9 as 
prognostic factors of tumor recurrence. 
 p-value HR (95% CI) 
Glucose (>119.5 mg/dL) 0.012 4.967 (1.415 – 17.434) 
TWBC (>6.8x10
3
/µL) 0.533 --- 
Lactate Dehydrogenase (>205.8 U/L) 0.025 3.835 (1.186 – 12.404) 
CA 19-9 (>14.5 ng/mL) 0.229 --- 
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Glucose and LDH stood out as independent prognostic factors of colorectal cancer recurrence with 
additional risks of 4.967 and 3.835, respectively (Table 4.12). 
 
CEA in Stage II and Stage III patients 
Of the factors that influenced CEA values in the prediction of recurrences presented in Section 
1.3.2.3, some were evaluated. The results regarding tumor stage are presented here. Other factors 
are presented in Section 5.2.1.  
 
Only patients with Stage II or III were selected and a ROC curve analysis was performed for the 
CEA’s predictive capability of recurrences  
 
Table 4.13 - Predictive capability of CEA in the sub-populations of stage II and stage III patients. 
 p-value Area under the ROC curve 95% CI 
Stage II 0.002 0.854 0.688 – 1.000 
Stage III 0.203 --- --- 
 
CEA has predictive capability in stage II but it does not in stage III by the analysis of the ROC 
Curves (Table 4.13). 
 
4.3. PRE-OPERATIVE DATA 
 
The descriptive statistics of this section, with the AUC already calculated for each parameter, are 
presented in Appendix I, Table I-4. 
 
After the analysis of the post-surgical, the pre-operative data was analyzed while looking for early 
prognostic signs given by the parameters that were tested in the post-surgical period. The ROC 
curves were plotted but unfortunately, all results lacked statistical significance, except for Alkaline 
Phosphatase.  
 
The best cut-off calculated for that parameter was 97.6 U/L with specificity, sensitivity and 
accuracy of 0.811, 0.545 and 0.750, respectively and an area under the ROC Curve of 0.726. 
 
That parameter was included in a Cox proportional hazards model but it did not reach significance 
(Table 4.14). 
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Table 4.14 - p-values of the ROC curve and Cox proportional hazards analyses of the selected parameters 
 ROC curve Univariate Cox Regression 
p-value Cut-off used (p-value) 
CEA 0.909  
CA 19-9  0.673  
TWBC  0.892  
Lactate Dehydrogenase  0.204  
C-reactive Protein 0.148  
Albumin 0.150  
Aspartate Aminotransferase 0.221  
Alkaline Phosphatase 0.024 >97.6 U/L (0.820) 
Gamma-GT 0.212  
 
These results are probably due to an even lower number of patients than in the post-surgical 
analysis and consequentially diminished quantity of data for each parameter (Table 4.15). The 
number of patients dropped to 107 and the number of recurrences to 17. 
 
Table 4.15 - Number and percentage of patients with recurrence for each of the analyzed parameters. 
 
Recurrence 
Yes Total 
CEA 2 (9%) 22 
CA 19-9 2 (11.1%) 18 
TWBC 17 (15.9%) 107 
Lactate Dehydrogenase 10 (23.8%) 42 
C-Reactive Protein 8 (19.5%) 41 
Albumin 3 (12.5%) 24 
Aspartate Aminotransferase 14 (19.4%) 72 
Alkaline Phosphatase 11 (22.9%) 48 
Gamma-GT 8 (19.0%) 42 
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CHAPTER 5: DISCUSSION 
 
The human body works like a great machine, composed of immense small mechanisms that interact 
with each other at many different levels. Some of these are known by current science but many still 
elude scientists and are slowly unraveled, bit by bit. The organism’s response to cancer still has 
many unknowns and will continue to be slowly comprehended. 
 
The biochemical analysis of the human blood has long been used to detect disturbances in the 
homeostasis that physicians know to be related with certain diseases. The different parameters 
evaluated in those analyses have reference ranges that are considered normal and science tells us 
that when one or more parameters are off the range, something is wrong.  
 
Maybe this principle of the reference ranges can be taken a bit further and, with a proper sample 
and adequate statistical methods, smaller changes in these parameters are detected as predictors of 
events long before the parameters get out of the reference range, clinical symptoms appear or 
perhaps some relationships between parameters and diseases are discovered. 
 
Based on that idea that maybe smaller changes in some parameters can be found related with 
pathological events, this study proposed to identify parameters that could be used as prognostic 
factors for colorectal cancer recurrences among clinical, clinicopathological and biochemical data 
of patients of the Oncology and Surgery Services of the Infante D. Pedro E.P.E Hospital. The data 
was collected in a retrospective method from the daily registries of those services.  
 
The study had some limitations. Infante D. Pedro E.P.E Hospital sends the records of deceased 
patients to an outsourced archive and their recovery has an associated cost that was not covered by 
the budget of this project. This resulted in a sample with more “alive” patients that what would be 
expected in an investigation on CRC which is clearly visible in the Patient Final State parameter 
(Table 4.1). Consequently, and since most patients who develop a recurrence have a reduced 
survival, the number of recurrences was also much smaller than what was expected and would be 
desirable for the purpose of the study. In addition, the laboratory data was not the same for every 
patient, existing missing data in almost all parameters. This limited the analyses even further as 
seen in Table 4.7. 
 
The first complete analysis carried out in this work concerned all the parameters included in the 
study. Most of those parameters were sequentially ruled out along the way according to the results 
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of the several statistical tools employed, until only the ones of most interest remained for the last 
analysis. 
 
The parameters that were included in the prognostic factor analysis were chosen with basis on two 
criteria: (a) the differences of the distribution of their values in the groups with and without 
recurrence (Table 4.4) and (b) plausibility of the relation with colorectal cancer. 
 
Hematological parameters like Erythrocytes, Hematocrit and Hemoglobin were not included 
because of possible chemotherapy influence. Neutrophils and Monocytes were not included since 
they are a partial parameter of the more global TWBC count. LDL Cholesterol was also 
significantly related with the occurrence of recurrences but since there were only two patients that 
had LDL values and experienced recurrence, it was not considered. The enzyme Lipase is usually 
involved in conditions related with the Pancreas (Dugdale, 2009b). Since this is not an organ 
usually targeted by CRC, the parameter was not further analyzed. 
 
5.1. CLINICOPATHOLOGICAL PARAMETERS 
 
This study was not able to address the parameters, except for one, introduced in Section 1.3.1, due 
to the low frequencies observed in those parameters (Table 1.3 and Table 4.5). Most of these 
characteristics were not frequently reported in the clinicopathologic reports. Moreover, their 
evaluation varies meaningfully from professional to professional and depends on the conditions of 
the surgical piece. Other authors have addressed the underreporting issue in a systematic way and 
concluded that these characteristics may offer more information than they currently do. 
 
The only parameter that had sufficient data to be analyzed was the Number of Examined Nodes. 
The results did not reach statistical significance but came very close to it (p = 0.058), agreeing with 
the literature data on colon cancer, that assigns an increased risk to patients who had less than 12 
nodes examined, recognizing it as an independent prognostic factor (Colon Cancer - NCCN, 2011). 
Conversely, the data that concerns rectal cancer exclusively has not provided conclusive results yet, 
but mentioned a negative influence of neoadjuvant therapy on the retrieval of nodes. 
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Figure 5.1 - Plot of the distribution of CEA values 
according to the ocurrence of CRC recurrence. 
5.2. POST-OPERATIVE DATA 
 
5.2.1. CEA 
 
The positive results obtained in the Cox proportional hazards model confirm a familiar scenario 
where Carcinoembryonic Antigen is concerned: CEA is the main biochemical marker in colorectal 
cancer. This is in line with current guideline recommendations(Colon Cancer - NCCN, 2011;Duffy 
et al., 2007;Labianca et al., 2010;Locker et al., 2006;Rectal Cancer - NCCN 2011) and a myriad of 
studies (Filiz et al., 2009;McCall et al., 1994;Rodriguez-Moranta et al., 2006;Tjandra et al., 
2007;Tsai et al., 2009;Wanebo et al., 1978;Watine et al., 2001). Although CEA is regarded as the 
best biochemical marker, TNM staging is considered the best prognostic factor in CRC. But since 
our distribution of data prevented the analysis of its relation with recurrence on an earlier phase, it 
was not included in the Cox regression model. 
 
The patients who experienced recurrence present significantly higher CEA values than the ones 
who remained disease-free (Table 4.4 and Figure 5.1). The univariate Cox regression provided a 
HR of around eight (p < 0.0001) for CEA much 
higher than any other parameter, which points 
to a major contribution to the risk of recurrence 
associated with values over 3.4 ng/mL. When 
analyzed in a multivariate model, the HR 
values drop to around five (p = 0.012), while a 
great rise in the p-value occurs. The great 
difference between the univariate and 
multivariate results can be explained by the 
missing data: when the Cox proportional 
hazards model is calculated, the number of 
cases is given by the patients who gather data 
on both the status and the independent variables. On the univariate analysis, the maximum number 
of cases is considered for each parameter. Once additional variables are added to the model, the 
number of cases is given by the intersection of all the parameters and the status variable. 
Consequently, it gets progressively smaller with each additional parameter. 
 
Together with the findings in the multivariate Cox proportional hazards model, which indicate that 
patients with serum CEA values above 3.4 ng/mL are between 1.429 and 18.903 times more likely 
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to develop a CRC recurrence than the others, with values below that level (Table 4.11), CEA is 
regarded as a good predictor of CRC recurrences. 
 
The reference range of CEA is 5.0 ng/mL for all patients, except for smokers, which is 10.0 ng/mL, 
at the laboratory of the IDPH. Those are in agreement to the values described in the literature 
(Duffy et al., 2003;Locker et al., 2006), but there are some mentions of lower reference values, like 
2.5 and 5.0 ng/mL for healthy people and smokers, respectively (Dugdale, 2009a).  
 
In the present study, the optimal cut-off was found at 3.4 ng/mL. Although it is higher than the new 
value considered in the literature, it is within the reference range considered in the hospital’s 
laboratory and recommended in the current guidelines from ASCO and EGTM that date from 2006 
and 2007, respectively. In addition, no information was gathered on smoking habits of the patients, 
what may have skewed the analysis. The best cut-off was considered only after half the recurrences 
were detected, what may elicit a lower value than only finding the value with the best accuracy. 
Nevertheless, that value was chosen instead of the bibliographic reference because it was the one 
that reflected the characteristics of this patient sample. 
 
Earlier in this text (Section 1.3.2.3), factors that interfere with the CEA pattern in the prediction of 
recurrences were referred and discussed: location and stage of the primary tumor, and recurrence 
location. 
 
Regarding tumor stage, this study contrasts with the ones previously cited (Hara et al., 2010;Park et 
al., 2006). In fact, the results point to a greater predictive power in stage II patients than stage III, 
but one has to consider that by splitting the already meager recurrence sample, the results get 
progressively weaker (Table 4.13) and there are only eight patients with both CEA measurements 
and recurrence with stage II disease and five with stage III.  
 
About recurrence location, the pattern of recurrence in this work does not allow a correct 
comparison since the group of liver metastases comprises more than half of the events and the 
remaining are scattered through other locations (Table 4.1). The data was further checked for a 
relationship between the initial place of the tumor and the place of the recurrence, but the relation 
between tumors of the rectum and local recurrences was not found (Table 5.1). 
 
Reaching results that agree with the literature on CEA is a good indicator that the data, however 
incomplete, is able to produce reliable results.  
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Figure 5.2 - Plot of the distribution of CA 19-9 values 
according to the ocurrence of CRC recurrence. 
Table 5.1 - Relation between the primary tumor's location and the location of the recurrences. 
Recurrence Location 
Primary Tumor Location 
Colon Rectum 
Hepatic 10 6 
Pulmonary 3 1 
Local 4 1 
Uterine 1 0 
Peritoneal 1 0 
Ovarian 1 0 
 
5.2.2. CA 19-9 
 
Carbohydrate Antigen 19-9 is not currently recommended in the European and American 
guidelines for diagnostic, prognostic or follow-up of CRC (Duffy et al., 2007;Locker et al., 2006). 
However, it is recommended by the Japanese 
Society for Cancer of the Colon and Rectum 
(Yakabe et al., 2010) for postoperative 
surveillance along with CEA. Moreover, this 
marker is empirically used in the clinical 
practice and, being readily available, was 
included in the study. 
 
Unsurprisingly, it was not found to be an 
independent prognostic factor in the multivariate 
analysis, although it was significantly elevated 
in patients that developed recurrences (Table 4.4 
and Figure 5.2) and patients with CA 19-9 above 14.6 ng/mL presented an increased risk of about 
three times (p = 0.038) for developing CRC recurrence by the univariate analysis (Table 4.10). 
 
The results from the ROC Curve analysis and univariate Cox proportional hazards model show us 
that it has some predictive capability, but when the bigger picture is considered, in the multivariate 
analysis, CEA is a much more complete factor, predicting all the recurrences that CA 19-9 does, 
and more. Although unlikely, because of the entire bibliographic consensus on the lack of utility of 
CA 19-9, the inherent properties of the Cox proportional hazards model, explained in Section 5.2.1, 
may also contribute to the lack of significance of CA 19-9 in the multivariate model. 
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Figure 5.3 - Plot of the distribution of Glucose values 
according to the ocurrence of CRC recurrence. 
5.2.3. Glucose 
 
Serum glucose was found to be a predictor of CRC recurrence in both uni- and multivariate 
analyses. Although no information was collected on dietary habits, height or weight, physical 
activity or lifestyle, high glucose levels may be related with some of these factors or an underlying 
disease like diabetes. 
 
The contribution of glucose to CRC management is not clear. If, on one hand, some studies find in 
their results a positive correlation, on the other, when a broad analysis is made, the conclusions 
point otherwise (Mulholland et al., 2009). The 
physiological rationale makes sense, but the 
attempts to bridge the glucose response or its 
levels with the effects of insulin on CRC and 
demonstrate those theories have not yet yielded 
conclusive results. 
 
To our knowledge, there is no study that 
assesses the risk of CRC recurrence with any of 
the aforementioned factors. In the current study, 
patients who develop recurrence have a slight, 
but significant (p = 0.010) tendency to higher 
blood glucose levels (Figure 5.3). The difference would probably be discarded if the parameter did 
not yield positive results in the following analyses (Table 4.9 to 4.12), indicating that that slight 
difference might be important. In fact, patients with blood glucose values over 119.5 mg/dL present 
a HR around 2.5, meaning that they have a risk of two and a half times greater of developing a 
recurrence than those patients with blood glucose values below that level. When a multivariate 
model is calculated, the HR associated with glucose actually rises to almost four in the patient 
sample (Table 4.11), contradicting the explanation provided in the Section 5.2.1 and maybe 
explaining part of the reduction in the risk associated only with CEA. The combination of these 
two parameters may contribute to an improved prediction of the recurrences. 
 
This is also, to our knowledge, the first study to establish a cut-off for this parameter in the 
recurrence of colorectal neoplasms. Moreover, glucose was the only parameter that was found to be 
a prognostic factor in the multivariate analysis, along with CEA (Table 4.11). This either means 
that the selected cut-off does not discriminate as well as it should, although it is above the upper 
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limit of the reference range in the IDPH’s laboratory, which is 60 – 110 mg/dL, or that glucose is in 
fact a good predictive factor for recurrence, at least for this patient sample. 
 
The results are in line with the previous studies that related glucose values with adenoma formation 
and colorectal cancer. 
 
Glucose must be taken into account with other characteristics of the patient like body measures, 
lifestyle, diet and other metabolic abnormalities. That data was not accounted for in this study and 
its collection would have been irregular due to the non-standardization of the information at the 
site. Nevertheless, these results are a hint of an approach to the use of this parameter in the big 
picture of colorectal cancer management.  
 
The information on whether the glucose values were obtained in fasting or fed conditions was not 
available, what may limit our conclusions. 
 
5.2.4. Liver Function Tests and Lactate Dehydrogenase 
 
Parameters that are usually part of the liver function tests, Aspartate Aminotransferase, Alkaline 
Phosphatase and Gamma-GT, along with Lactate Dehydrogenase were selected in the inter-group 
analysis for that same reason: being related with liver function, since the liver is the main place of 
occurrence of distant metastases (Hara et al., 2010;Tsai et al., 2009). 
 
Except for LDH, none of the other parameters demonstrated significant predictive capability in the 
ROC Curve analysis (Table 4.9) although they had proven to be significantly elevated in the 
patients who experienced recurrence (Figure 5. to Figure 5. and Table 4.4). There have not been 
many recent studies evaluating the part LFTs play in CRC management, but from a review of 
studies since 1974, there seems to be some uncertainty on the role of LFTs in the detection of CRC 
recurrences. 
 
Rocklin et al. (Rocklin et al., 1991) found that, when compared with CEA, the use of LFTs does 
not provide substantial additional information. Ohlsson et al. (Ohlsson et al., 1995) examined 
intensive follow-up in CRC patients and besides the lack of evidence that the intensive follow-up 
provided additional benefit on a regular basis, within the blood tests, LFTs had a negligible 
contribution to the detection of recurrences, with CEA playing the main role. On yet another study, 
LFTs were found to be useful in the detection of metastases when CEA exceeded 500 ng/mL and 
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Gamma-GT 100 U/L. These are high values for these variables, which may render the 
measurement of LFTs useless because at such high CEA concentrations, imaging or surgical 
procedures would be triggered anyway (Cooper et al., 1975). 
 
 
 
Gamma-GT, when used in conjunction with CEA, has been found to help in the differentiation 
between hepatic metastases and others (Steele et al., 1974). The low number of patients with 
hepatic recurrences and Gamma-GT (n = 8) measurements prevented a proper study of this 
characteristic in the present study, with the parameters not reaching statistical significance in the 
ROC Curve calculation. 
 
 
 
Figure 5.5 - Plot of the distribution of ALP according 
to the ocurrence of CRC recurrence. 
Figure 5.4 - Plot of the distribution of AST values 
according to the ocurrence of CRC recurrence. 
Figure 5.7 - Plot of the distribution of LDH values 
according to the ocurrence of CRC recurrence. 
Figure 5.6 - Plot of the distribution of Gamma-GT 
values according to the ocurrence of CRC 
recurrence. 
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Lactate dehydrogenase does not specifically reflect liver function, although it is frequently 
requested along with the liver function tests. Instead, it reflects tissue breakdown (Vorvick, 2010). 
In case of colorectal cancer, it may reflect (a) the tissue damage caused by the tumor – e.g.: in the 
liver in the case of a metastasis or (b) the presence of tumor growth due to the high rate of cellular 
turnover. In either case, a rise in its values may raise a suspicion. 
 
LDH took significantly higher values in patients who experienced recurrence (Figure 5. and Table 
4.4). In addition, in the univariate Cox proportional hazards model, LDH values over 205.8 U/L 
presented an additional risk of about two and a half times greater than lower or equal values with a 
p-value of 0.049 (Table 4.10). Although these numbers are on the borderline of statistical 
significance, an analysis with a greater number of subjects would allow for a better determination 
of the real predictive power of this (and other) parameters. 
 
When included in the multivariate analysis with the Cox proportional hazards model, LDH failed to 
contribute with any prognostic information that CEA did not already provide (Table 4.11). 
However, when CEA was removed from the analysis, LDH posed an additional risk of almost four 
times for the developing of recurrences (Table 4.12), alongside with Glucose. 
 
Between the multivariate Cox regressions with and without CEA, there is no change in the number 
of cases. Henceforth, the differences observed in LDH are probably explained by the greater 
prognostic capability of CEA, whose rise poses a much greater risk for recurrence when compared 
with LDH. 
 
5.2.5. Inflammation markers 
 
The parameters of C-Reactive Protein, Albumin and TWBC were selected from the inter-group 
tests because they usually translate, to some degree, the body’s response to an unknown entity or 
other stimulus in (a) an inflammatory response or (b) an infection. Since cancer cells are 
recognized by the immune system as foreign to the host, both these responses are frequently 
present. 
 
5.2.5.1. CRP 
 
C-Reactive Protein has been found useful in several studies (Aleksandrova et al., 2010;Crozier et 
al., 2006;Ishizuka et al., 2009;Koike et al., 2008;McMillan et al., 1995;Sharma et al., 2008). It has 
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Figure 5.4 - Plot of the distribution of CRP according 
to the ocurrence of CRC recurrence. 
been considered independently and together with albumin in an inflammation score named 
Glasgow Prognostic Score (GPS) which categorizes patients into three levels according to CRP and 
Albumin cut-offs of 10 mg/dL and 3.5 g/dL 
respectively. When CRP is elevated (CRP > 10 
mg/dL) and hypoalbuminemia is present 
(Albumin < 3.5 g/dL) the score of 2 is 
attributed. When only one of those conditions is 
satisfied the score 1 is credited. Finally, when 
none is present, the allocated score is 0. 
 
In a brief summary of the studies mentioned 
above, CRP provided useful information related 
to (a) colon cancer (but not rectal) risk 
predominantly in men, (Aleksandrova et al., 
2010), (b) the prediction of survival (in the context of GPS) of patients with stage IV disease 
(Sharma et al., 2008), (c) the need of adjuvant chemotherapy in stage II patients (preoperative CRP  
were used) (Koike et al., 2008), (d) the prediction of poor outcome in patients receiving adjuvant 
chemotherapy (Crozier et al., 2006), (e) patients with stage IV disease with liver metastases 
(Ishizuka et al., 2009) and (f) the detection of recurrences (McMillan et al., 1995).  
 
The results of the present study show that there are more high CRP values in the group of patients 
that experienced recurrences with a p = 0.031 in Table 4.4 (Figure 5.4), but the ROC Curve 
analysis demonstrated that the parameter did not provide significant results towards the detection of 
recurrences (p = 0.08), maybe because there are also high values in the non-recurrence group, albeit 
in less quantity. Kwon et al. found similar results when evaluating preoperative CRP towards 
survival (Kwon et al., 2010). The higher values in the recurrence group are consistent with studies 
that report elevated CRP in patients with advanced disease, but the absence of predictive capability 
is in contrast with the results obtained by McMillan et al. (McMillan et al., 1995), since they found 
CRP to detect recurrences even earlier than CEA, even though they presented a small patient 
sample.  
 
The patient sample in the present study may not have been large enough to grant statistical power 
to this parameter. However, it came close to statistical significance in the ROC Curve analysis, 
perceiving a possible improvement in a larger sample. 
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5.2.5.2. Albumin 
 
As referred before, in Section 1.3.2.1, the decrease 
of preoperative serum Albumin may present as an 
early sign of malignancy. Accordingly, a 
systematic review by Gupta and Lis (Gupta et al., 
2010) found pretreatment albumin to be suitable 
for defining baseline risk in clinical trials in 
oncology, but also that there is a lack of knowledge 
on whether raised levels decrease the excess risk of 
mortality. 
 
In the current study, albumin values are 
significantly lower in the patients who experience 
recurrence in the inter-group analysis (Table 4.4 and Figure 5.5). However, albumin failed to 
provide significant prognostic information in the ROC curve analysis (Table 4.9). 
 
Albumin has been considered as a pre-surgical prognostic factor. The mobilization of proteins for 
acute-phase synthesis, leading to a cachectic state in the establishment of an inflammatory response 
appears to be reasonable. Since most patients are only diagnosed with CRC at a somewhat 
advanced stage, the cachectic syndrome has had time to settle and slowly deplete the body’s protein 
reserve. In the case of recurrent patients, they are more alert to the dangers of malnourishment and 
are alert for signs of the disease. They are also monitored more frequently, providing opportunity 
for correcting transient deficiencies in proteins.  
 
5.2.5.3. Total White Blood Cells 
 
The count of Total White Blood Cells is used to check if an inflammatory process is in place or an 
infection is present. In the context of rectal cancer, it has been found to be increased in advanced 
stages of the disease (Janisch et al., 1994;Shoenfeld et al., 1986) and terminal patients (Ventafridda 
et al., 1991), related with shorter survival (Maltoni et al., 1997) and significantly correlated with 
the presence of metastases in several malignancies, including colorectal However, metastasis was 
not an obligatory requirement for the presence leukocytosis (Shoenfeld et al., 1986). 
 
Figure 5.5 - Plot of the distribution of Albumin 
values according to the ocurrence of CRC 
recurrence. 
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Figure 5.6 - Plot of the distribution of TWBC values 
according to the ocurrence of CRC recurrence. 
The pathophysiological processes that underlie 
the changes in TWBC counts are not clear. 
The elevation may be a result of direct or 
indirect processes such as (a) necrosis or 
inflammation or (b) effects on bone marrow or 
peripheral TWBC pools, respectively (Maltoni 
et al., 1997).  
 
In the present study, the white blood cell count 
was significantly higher in patients that 
experienced recurrences (Table 4.4 and Figure 
5.6). 
 
TWBC’s predictive capability was the third best in the ROC Curve analysis and patients with 
values above 6.8x10
3
/µL were found at an increased risk of recurrence of about two times (Table 
4.10). However, when included in a multivariate model, the remaining parameters were found more 
powerful in the prediction of recurrences (Table 4.11 and Table 4.12). The explanation provided in 
Section 5.2.1, concerning the characteristics of the statistical method employed, may also 
contribute to this loss of capability and the data must be interpreted with caution. 
 
These findings need an extra-careful interpretation because the cut-off found in the ROC Curve 
analysis is well within the reference range for this parameter, 11.10x10
3
/µL, and a patient with 6.8 
cannot be considered at greater risk of recurrence because it is a normal TWBC value. However, 
these results may point to a tendency towards higher values being related with recurrence, what 
would be in line with the results obtained in the aforementioned studies. 
 
5.3. PRE-OPERATIVE DATA 
 
In the ideal scenario, it would be possible to know, based on clinicopathological and biochemical 
data, if a patient is at high risk of developing a recurrence even before the curative resection of the 
primary tumor takes place. To that end, the parameters that had given promising signs in the early 
post-operative analysis were tested in the pre-surgical data, with negative results.  
 
The only parameter that presented diagnostic capability was Alkaline Phosphatase in the ROC 
Curve analysis. Unfortunately, this parameter did not reach statistical significance in the Cox 
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proportional hazards model, proving that patients with elevated ALP are not at an increased risk of 
developing CRC recurrences. 
 
The pre-operative database was even further reduced than the post-operative because, for many 
patients, that information was not readily available from their records in either format, paper or 
electronic. Additionally, an already reduced pool of 151 patients was reduced to 107, with only 17 
recurrences and an even more reduced amount of data on each parameter (Table 4.15). This will 
have no doubt contributed to the negative results and only a more powerful study on these 
parameters will have the ability to study it thoroughly. 
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CHAPTER 6: CONCLUSIONS 
 
Colorectal cancer is one of the leading causes of death of the modern world. The death rate is 
exceedingly high in advanced stages and even if detected in an early phase and potentially curative 
resection is performed, 40 to 50% of the patients will develop recurrence or metastatic disease 
(Kievit, 2002). The recurrence risk must be characterized as thoroughly as possible in order to 
identify that subset of patients and assign them to the best possible therapeutic plan. 
 
Although there are markers already identified for recurrence like TNM Staging and 
Carcinoembryonic Antigen, they are still unable to predict it with precision. Consequently, all the 
sources of extra input on recurrence can be of great interest to patient management. 
 
Although largely underpowered by the scarce number of patients with recurrences and deaths, it 
was possible to produce reliable results as can be seen by the conformity of the data on CEA and 
CA 19-9 with the literature.  
 
The strongest predictor found in the analysis, aside from CEA, was blood glucose. The data on this 
parameter in colorectal cancer is conflicting and this study approached the subject from a different 
angle of the ones before it. Nevertheless, the rationale makes sense with the data, even though the 
difference between the values of the patients with and without recurrences is slight, but coherent 
through all the analyses. 
 
C-Reactive Protein is a possible predictor of recurrence since it came very close to statistical 
significance in this work. A study with a larger sample will probably be able to shed more light on 
this parameter.  
 
TWBC has to be further investigated, but the tendency towards a relation between high TWBC 
values and recurrence is signaled here. 
 
Albumin values did not provide information on this work and the literature only considers its role 
on the preoperative period. The parameter appears to be of no use in the prediction of recurrences. 
 
Liver function tests did not provide useful input as predictors although they are empirically used in 
the clinic since there is a logical relation between the possibility of a patient harboring liver 
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metastases and raised hepatic tests. Maybe Gamma-GT is in fact useful in that scenario but this 
work could not evaluate it properly. 
 
Lactate Dehydrogenase, not being liver specific but frequently associated with its function, 
provided significant results that must be taken into account even though they were only useful if 
CEA was not considered in this analysis. The sample limitations do not allow an extrapolation that 
clearly states that it will only be useful if CEA is not measured. 
 
Given the inherent limitations, the results are merely indicative, with very large confidence 
intervals. Nevertheless, the hint that blood glucose and perhaps lactate dehydrogenase may 
contribute to the assessment of recurrence risk along with CEA is an important result that invites 
confirmation by future, more powerful studies. 
 
Studies of this nature are ideally performed on clinical data that has been registered under clear 
rules and organization. Collecting and organizing data from the daily clinical registries, in both 
paper and electronic formats, that was reported without standard reporting rules tends to be a 
difficult job. The results obtained in this study prove that it is not absolutely necessary to have the 
ideal registries to produce relevant results in health and expand scientific knowledge, walking 
towards improved medical care and that this is a possible repository of knowledge worth exploring. 
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APPENDIX I APPENDIX 
 
Table I-1 - Descriptive statistics of post-surgical biochemical data 
 n    
 Valid Missing Median Minimum Maximum 
Erythrocytes 2318 113 4.1 1.8 6.5 
Hemoglobin 2318 113 12.4 6.1 17.5 
Hematocrit 2318 113 37.7 17.6 54.7 
Mean Corpuscular Volume 2318 113 92.0 56.0 121.0 
Mean Corpuscular Hemoglobin 2318 113 30.4 16.0 40.8 
MCHC 2317 114 33.0 25.4 90.8 
RDW 2283 148 13.6 9.9 31.5 
Total White Blood Cells 2317 114 6.2 0.3 52.4 
Neutrophils 2315 116 3.8 0.0 46.7 
Eosinophils 2313 118 0.1 0.0 2.1 
Basophils 2313 118 0.0 0.0 1.0 
Lymphocytes 2313 118 1.5 0.0 7.7 
Monocytes 2312 119 0.4 0.0 9.8 
Platelets 2305 126 213.0 6.0 1291.0 
Erythrocyte Sedimentation Rate 184 2247 18.0 2.0 128.0 
Prothrombin Time 630 1801 12.3 9.6 53.6 
International Normalized Ratio 628 1803 1.0 0.0 4.8 
Thromboplastin Time 564 1867 28.9 12.4 155.0 
Glucose 2021 410 107.9 51.7 494.0 
Blood Urea Nitrogen 2005 426 35.4 0.8 261.7 
Creatinine 2005 426 0.9 0.2 60.4 
Sodium 1956 475 139.3 101.0 170.1 
Potassium 1955 476 4.3 2.1 6.5 
Chloride 1948 483 104.0 76.0 139.0 
Calcium 747 1684 8.9 3.1 10.7 
Phosphorus 353 2078 2.9 0.5 10.1 
Magnesium 530 1901 2.0 1.0 4.2 
Creatine Phosphokinase 134 2297 81.5 8.0 1257.0 
Aspartate Aminotransferase 1526 905 22.0 6.0 377.0 
Alanine Aminotransferase 1521 910 30.0 3.0 440.0 
Lactate Dehydrogenase 1297 1134 194.0 32.0 2799.0 
Bilirubin - Total 1195 1236 0.6 0.1 10.0 
Bilirubin - Direct 1095 1336 0.1 0.0 5.7 
Bilirubin - Indirect 1094 1337 0.5 0.0 4.3 
Alkaline Phosphatase 1335 1096 91.0 25.0 2037.0 
Gamma-GT 1149 1282 37.0 4.0 1336.0 
C-Reactive Protein 447 1984 4.1 0.0 33.8 
Total Proteins 431 2000 7.0 2.7 8.6 
Albumin 490 1941 3.8 0.7 5.2 
Uric Acid 247 2184 4.9 1.9 10.3 
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 n    
 Valid Missing Median Minimum Maximum 
Cholesterol - Total 177 2254 198.0 7.0 371.0 
Cholesterol - HDL 155 2276 49.6 6.9 271.0 
Cholesterol - LDL 138 2293 128.5 8.0 253.0 
Triglycerides 162 2269 110.0 32.0 527.0 
Amylase 114 2317 51.0 8.0 479.0 
Lipase 116 2315 64.5 1.0 2013.0 
Iron 119 2312 80.0 18.0 219.4 
Ferritin 84 2347 70.0 4.0 1253.0 
Alpha-Fetoprotein 136 2295 1.9 0.9 20.5 
CEA 1019 1412 1.4 0.0 823.0 
CA 19-9 985 1446 10.8 1.2 462.9 
PSA 85 2346 0.9 0.2 4172.0 
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Table I-2 - Correlation coefficient of biochemical variables with CEA and CA 19-9. 
 Spearman Correlation Coefficient 
 CEA (p) CA 19-9 (p) 
CEA --- 0.281 (<0.0001) 
CA 19-9 0.281 (<0.0001) --- 
Erythrocytes -0.102 (0.001) -0.033 (0.306) 
Hemoglobin -0.096 (0.002) -0.021 (0.516) 
Hematocrit -0.07 (0.027) -0.02 (0.532) 
Mean Corpuscular Volume 0.118 (<0.001) 0.081 (0.012) 
Mean Corpuscular Hemoglobin 0.061 (0.055) 0.094 (0.003) 
MCHC -0.134 (<0.001) 0.015 (0.645) 
RDW 0.095 (0.003) -0.035 (0.28) 
Total White Blood Cells 0.138 (<0.001) 0.074 (0.022) 
Neutrophils 0.123 (<0.001) 0.109 (0.001) 
Eosinophils 0.08 (0.012) -0.049 (0.131) 
Basophils -0.07 (0.028) 0.008 (0.816) 
Lymphocytes -0.023 (0.475) -0.043 (0.187) 
Monocytes 0.203 (<0.001) 0.083 (0.01) 
Platelets 0.062 (0.051) 0.154 (<0.001) 
Erythrocyte Sedimentation Rate -0.017 (0.837) 0.016 (0.849) 
Prothrombin Time 0.047 (0.677) 0.135 (0.235) 
International Normalized Ratio 0.06 (0.591) 0.168 (0.139) 
Thromboplastin Time 0.248 (0.031) -0.001 (0.993) 
Glucose 0.192 (<0.001) 0.125 (<0.001) 
Blood Urea Nitrogen -0.094 (0.005) 0.008 (0.825) 
Creatinine -0.025 (0.455) 0.067 (0.051) 
Sodium -0.133 (<0.001) -0.11 (0.002) 
Potassium -0.072 (0.038) -0.076 (0.032) 
Chloride -0.016 (0.654) -0.12 (0.001) 
Calcium -0.063 (0.186) -0.196 (<0.001) 
Phosphorus -0.054 (0.421) 0.188 (0.005) 
Magnesium -0.211 (<0.001) -0.059 (0.283) 
Creatine Phosphokinase 0.392 (0.233) -0.119 (0.713) 
Aspartate Aminotransferase 0.2 (<0.001) 0.114 (0.001) 
Alanine Aminotransferase -0.066 (0.053) 0.029 (0.402) 
Lactate Dehydrogenase 0.356 (<0.001) 0.179 (<0.001) 
Bilirubin – Total 0.098 (0.009) -0.025 (0.524) 
Bilirubin – Direct 0.119 (0.003) 0.069 (0.092) 
Bilirubin – Indirect 0.086 (0.031) -0.063 (0.123) 
Alkaline Phosphatase 0.038 (0.281) 0.223 (<0.001) 
Gamma-Glutamyltransferase 0.196 (<0.001) 0.284 (<0.001) 
C-Reactive Protein 0.294 (0.005) 0.013 (0.906) 
Total Proteins -0.174 (0.004) <0.001 (0.998) 
Albumin -0.119 (0.039) -0.16 (0.006) 
Uric Acid 0.16 (0.022) 0.181 (0.01) 
Cholesterol – Total 0.35 (<0.001) 0.146 (0.113) 
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 Spearman Correlation Coefficient 
 CEA (p) CA 19-9 (p) 
Cholesterol – HDL 0.037 (0.705) 0.2 (0.037) 
Cholesterol – LDL 0.407 (<0.001) 0.06 (0.546) 
Triglycerides 0.287 (0.002) 0.382 (<0.001) 
Amylase 0.203 (0.7) 0.071 (0.879) 
Lipase -0.036 (0.939) 0.214 (0.645) 
Iron -0.026 (0.79) 0.059 (0.553) 
Ferritin 0.159 (0.176) 0.317 (0.006) 
Alpha-Fetoprotein -0.214 (0.014) 0.172 (0.051) 
PSA 0.199 (0.116) -0.141 (0.266) 
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Table I-3 - Mann-Whitney U tests of biochemical variables across groups of patients with and without recurrence. 
 Recurrence  
 No Yes p-value 
Erythrocytes 124 28 0.003 
Hemoglobin 124 28 0.004 
Hematocrit 124 28 0.002 
Mean Corpuscular Volume 124 28 0.676 
Mean Corpuscular Hemoglobin 124 28 0.748 
Mean Corpuscular Hemoglobin Concentration 124 28 0.788 
 Red Blood Cell Distribution Width 124 28 0.621 
Total White Blood Cells 124 28 0.022 
Neutrophils 124 28 0.007 
Eosinophils 124 28 0.395 
Basophils 124 28 0.572 
Lymphocytes 124 28 0.044 
Monocytes 124 28 0.021 
Platelets 124 28 0.266 
Erythrocyte Sedimentation Rate 17 2 0.595 
Prothrombin Time 87 24 0.443 
International Normalized Ratio 87 24 0.559 
Thromboplastin Time 77 22 0.920 
Glucose 124 28 0.010 
Blood Urea Nitrogen 124 28 0.951 
Creatinine 124 28 0.260 
Sodium 123 28 0.485 
Potassium 123 28 0.041 
Chloride 123 28 0.444 
Calcium 78 25 0.633 
Phosphorus 51 23 0.843 
Magnesium 62 24 0.331 
Creatine Phosphokinase 21 11 0.858 
Aspartate Aminotransferase 110 28 0.010 
Alanine Aminotransferase 110 28 0.571 
Lactate Dehydrogenase 102 28 <0.001 
Bilirubin - Total 100 27 0.920 
Bilirubin - Direct 96 27 0.085 
Bilirubin - Indirect 95 27 0.476 
Alkaline Phosphatase 105 28 0.014 
Gamma-GT 99 26 0.048 
C-Reactive Protein 51 19 0.031 
Total Proteins 56 21 0.075 
Albumin 60 21 0.034 
Uric Acid 37 7 0.810 
Cholesterol - Total 31 3 0.316 
Cholesterol - HDL 27 3 0.090 
Cholesterol - LDL 22 2 0.047 
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 Recurrence  
 No Yes p-value 
Triglycerides 29 3 0.146 
Amylase 11 8 0.901 
Lipase 14 8 0.041 
Iron 24 2 0.124 
Ferritin 20 1 0.620 
Alpha-Fetoprotein 17 6 0.183 
CEA 113 23 <0.0001 
CA 19-9 114 23 <0.0001 
PSA 11 2 0.324 
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Table I-4 – Descriptive statistics of pre-surgical biochemical data 
 n    
 Valid Missing Median Minimum Maximum 
Erythrocytes 107 0 4.4 3.4 5.9 
Hemoglobin 107 0 12.6 8.1 24.6 
Hematocrit 107 0 38.4 27.7 50.7 
Mean Corpuscular Volume 107 0 88.8 57.7 100.3 
Mean Corpuscular Hemoglobin 107 0 29.4 17.2 33.2 
MCHC 107 0 32.5 29.1 35.1 
RDW 101 6 14.3 11.3 24.1 
Total White Blood Cells 107 0 7.0 3.1 19.8 
Neutrophils 106 1 4.5 1.3 16.2 
Eosinophils 106 1 0.2 0.0 0.8 
Basophils 106 1 0.0 0.0 0.1 
Lymphocytes 106 1 1.7 0.1 7.0 
Monocytes 106 1 0.5 0.2 2.3 
Platelets 101 6 271.5 64.4 598.6 
Erythrocyte Sedimentation Rate 21 86 27.5 5.5 51.5 
Prothrombin Time 83 24 11.8 10.1 18.7 
International Normalized Ratio 83 24 1.0 0.8 1.6 
Thromboplastin Time 72 35 27.1 21.8 45.9 
Glucose 97 10 105.2 75.6 322.7 
Blood Urea Nitrogen 93 14 38.1 12.0 118.9 
Creatinine 94 13 0.9 0.6 2.0 
Sodium 89 18 139.5 120.9 152.0 
Potassium 89 18 4.4 3.5 5.8 
Chloride 89 18 103.3 96.5 124.2 
Calcium 7 100 6.5 4.8 9.4 
Phosphorus 2 105 1.4 1.2 1.6 
Magnesium 2 105 2.1 1.9 2.3 
Creatine Phosphokinase 14 93 45.8 18.0 144.5 
Aspartate Aminotransferase 72 35 20.5 6.5 144.5 
Alanine Aminotransferase 70 37 21.9 10.0 157.1 
Lactate Dehydrogenase 42 65 179.2 114.0 303.5 
Bilirubin - Total 49 58 0.7 0.1 1.6 
Bilirubin - Direct 41 66 0.1 0.1 0.7 
Bilirubin - Indirect 41 66 0.5 0.3 1.1 
Alkaline Phosphatase 48 59 75.0 43.0 196.8 
Gamma-GT 42 65 24.8 8.5 204.0 
C-Reactive Protein 41 66 2.2 0.1 22.6 
Total Proteins 20 87 6.8 5.9 7.7 
Albumin 24 83 3.9 3.0 4.7 
Uric Acid 18 89 5.2 3.0 7.5 
Cholesterol - Total 15 92 215.0 135.4 265.0 
Cholesterol - HDL 14 93 48.1 30.5 65.0 
Cholesterol - LDL 12 95 128.8 80.0 175.0 
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 n    
 Valid Missing Median Minimum Maximum 
Triglycerides 14 93 137.3 56.0 171.0 
Amylase 15 92 43.5 24.5 572.8 
Lipase 14 93 82.5 6.0 1846.0 
Iron 6 101 17.9 11.5 31.2 
Ferritin 7 100 20.0 7.5 261.9 
Alpha-Fetoprotein 6 101 1.5 1.0 2.6 
CEA 22 85 2.4 0.5 176.2 
CA 19-9 18 89 10.2 2.5 105.7 
PSA 10 97 1.2 0.2 6.4 
 
 
